|
US5376645A
(en)
*
|
1990-01-23 |
1994-12-27 |
University Of Kansas |
Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
|
|
US5262404A
(en)
*
|
1990-02-15 |
1993-11-16 |
The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation |
Cyclodextrin polymers and cyclodextrins immobilized on a solid surface
|
|
KR927003645A
(ko)
|
1990-05-21 |
1992-12-18 |
후지다 히로미찌 |
씨클로덱스트린 유도체
|
|
JP2556236B2
(ja)
*
|
1991-08-29 |
1996-11-20 |
田辺製薬株式会社 |
β−シクロデキストリン誘導体のポリ硫酸エステル及びその製法
|
|
WO1993007904A1
(en)
*
|
1991-10-16 |
1993-04-29 |
Schering Corporation |
Lipophilic oligosaccharide antibiotic salt compositions
|
|
DE4204315A1
(de)
*
|
1992-02-13 |
1993-08-19 |
Consortium Elektrochem Ind |
Cyclodextringlycoside und verfahren zu ihrer herstellung
|
|
US5403828A
(en)
*
|
1992-08-13 |
1995-04-04 |
American Maize-Products Company |
Purification of cyclodextrin complexes
|
|
US6114355A
(en)
*
|
1993-03-01 |
2000-09-05 |
D'amato; Robert |
Methods and compositions for inhibition of angiogenesis
|
|
US5629327A
(en)
*
|
1993-03-01 |
1997-05-13 |
Childrens Hospital Medical Center Corp. |
Methods and compositions for inhibition of angiogenesis
|
|
US6228879B1
(en)
|
1997-10-16 |
2001-05-08 |
The Children's Medical Center |
Methods and compositions for inhibition of angiogenesis
|
|
US8143283B1
(en)
|
1993-03-01 |
2012-03-27 |
The Children's Medical Center Corporation |
Methods for treating blood-born tumors with thalidomide
|
|
DE4309579C3
(de)
*
|
1993-03-24 |
2000-01-27 |
Sanol Arznei Schwarz Gmbh |
Pharmazeutische Zusammensetzung in Form einer Packung
|
|
DE4313408A1
(de)
*
|
1993-04-23 |
1994-10-27 |
Boehringer Mannheim Gmbh |
Cyclodextrin-Biocid-Komplex
|
|
HU213200B
(en)
*
|
1993-05-12 |
1997-03-28 |
Chinoin Gyogyszer Es Vegyeszet |
The cyclodextrin or cyclodextrin derivative cluster complexes of taxol, taxotere, or taxus, pharmaceutical preparations containing them and process for their production
|
|
CZ306394A3
(en)
*
|
1993-12-14 |
1995-08-16 |
Lilly Co Eli |
Aqueous solution of inclusion complex of benzothiophene derivative with water-soluble cyclodextrins, process of its preparation and a pharmaceutical composition containing thereof
|
|
US5443824A
(en)
*
|
1994-03-14 |
1995-08-22 |
Piacquadio; Daniel J. |
Topical thalidomide compositions for surface or mucosal wounds, ulcerations, and lesions
|
|
DE4429229A1
(de)
*
|
1994-08-18 |
1996-02-22 |
Consortium Elektrochem Ind |
Cyclodextrinderivate mit mindestens einem stickstoffhaltigen Heterozyklus, ihre Herstellung und Verwendung
|
|
EP0709099A3
(de)
*
|
1994-09-28 |
1996-07-24 |
Senju Pharma Co |
Wässrige Suspension zur nasalen Verabreichung enthaltend Cyclodextrin
|
|
US5468502A
(en)
*
|
1994-12-20 |
1995-11-21 |
American Home Products Corporation |
Ibuprofen enhancing solvent system
|
|
BE1008978A5
(fr)
*
|
1994-12-27 |
1996-10-01 |
Solvay |
Adjuvants pour vaccins.
|
|
US6429221B1
(en)
*
|
1994-12-30 |
2002-08-06 |
Celgene Corporation |
Substituted imides
|
|
DE19505263A1
(de)
*
|
1995-02-16 |
1996-08-22 |
Consortium Elektrochem Ind |
Verfahren zur Reinigung von wasserlöslichen Cyclodextrinderivaten
|
|
AU5774796A
(en)
*
|
1995-06-13 |
1997-01-09 |
Dyer, Alison Margaret |
Pharmaceutical compositions containing lornoxicam and cyclod extrin
|
|
US6346510B1
(en)
|
1995-10-23 |
2002-02-12 |
The Children's Medical Center Corporation |
Therapeutic antiangiogenic endostatin compositions
|
|
HUT75956A
(en)
*
|
1995-11-29 |
1997-05-28 |
Cyclolab |
Pharmaceutical composition containing thyroxine
|
|
GB9605705D0
(en)
|
1996-03-19 |
1996-05-22 |
Pfizer Ltd |
Therapeutic agents
|
|
DE69733664T3
(de)
|
1996-04-19 |
2011-04-14 |
Grifols Inc. (n.d. Ges.d.Staates Delaware), Los Angeles |
Verfahren zur INaktivierung von Viren und Lyophilisierung von Blutproteinen
|
|
UA57734C2
(uk)
|
1996-05-07 |
2003-07-15 |
Пфайзер Інк. |
Комплекси включення арилгетероциклічних солей
|
|
US5906981A
(en)
*
|
1996-06-04 |
1999-05-25 |
Troy Corporation |
Halopropargyl inclusion complexes
|
|
EP1920773B1
(de)
*
|
1996-11-05 |
2011-01-05 |
The Children's Medical Center Corporation |
Thalidomide und Dexamethason für die Behandlung von Tumors
|
|
KR100411289B1
(ko)
*
|
1996-11-29 |
2004-02-14 |
주식회사 포스코 |
회전장애 이성질체의 분리에 유용한 6-알릴디메틸실릴-2,3-디에 틸-베타-시클로덱스트린 및 그 제조방법
|
|
KR100435426B1
(ko)
*
|
1996-11-29 |
2004-08-16 |
주식회사 포스코 |
구조 이성질체의 분리에 유용한 6-디메틸옥틸실릴-2,3-디에틸-베타-시클로덱스트린 및 그 제조방법
|
|
DE19713092A1
(de)
*
|
1997-03-27 |
1998-10-01 |
Wacker Chemie Gmbh |
Komplexe aus Gamma-Cyclodextrin und Retinol bzw. Retinol-Derivaten sowie Verfahren zu ihrer Herstellung und ihre Verwendung
|
|
US5874418A
(en)
*
|
1997-05-05 |
1999-02-23 |
Cydex, Inc. |
Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use
|
|
RU2173172C2
(ru)
*
|
1997-05-05 |
2001-09-10 |
Сайдекс Инк. |
Твердые фармацевтические препараты, содержащие физическую смесь сульфоалкилового эфира циклодекстрина и терапевтического агента
|
|
US6046177A
(en)
*
|
1997-05-05 |
2000-04-04 |
Cydex, Inc. |
Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
|
|
ES2210769T3
(es)
*
|
1997-06-13 |
2004-07-01 |
Cydex Inc. |
Compuesto con vida de almacenamiento prolongada que comprende ciclodextrina y medicamentos y promedicamentos que se descomponen en componentes insolubles en agua.
|
|
GB9713149D0
(en)
*
|
1997-06-21 |
1997-08-27 |
Pfizer Ltd |
Pharmaceutical formulations
|
|
ES2257795T3
(es)
*
|
1997-07-01 |
2006-08-01 |
Pfizer Products Inc. |
Procedimiento para producir una ciclodextrina.
|
|
US6391862B1
(en)
*
|
1997-10-14 |
2002-05-21 |
The Texas A&M University System |
Chiral resolving agents for enantioseparations
|
|
US6699849B1
(en)
*
|
1998-02-23 |
2004-03-02 |
Cyclops, Ehf. |
Cyclodextrin complexes of benzodiazepines
|
|
WO1999042111A1
(en)
*
|
1998-02-23 |
1999-08-26 |
Cyclops, Ehf. |
High-energy cyclodextrin complexes
|
|
US6048736A
(en)
*
|
1998-04-29 |
2000-04-11 |
Kosak; Kenneth M. |
Cyclodextrin polymers for carrying and releasing drugs
|
|
US6673828B1
(en)
|
1998-05-11 |
2004-01-06 |
Children's Medical Center Corporation |
Analogs of 2-Phthalimidinoglutaric acid
|
|
DE19825486C2
(de)
|
1998-06-08 |
2000-07-06 |
Stockhausen Chem Fab Gmbh |
Wasserabsorbierende Polymere mit supramolekularen Hohlraummolekülen, Verfahren zu deren Herstellung und deren Verwendung
|
|
NZ330726A
(en)
*
|
1998-06-18 |
2000-10-27 |
Dec Res |
Intra-vaginal delivery unit or composition containing a cyclodextrin which improves absorbtion of 17-beta oestradiol or oestradiol benzoate
|
|
WO2000012137A1
(en)
*
|
1998-09-02 |
2000-03-09 |
Allergan Sales, Inc. |
Preserved cyclodextrin-containing compositions
|
|
US20020198174A1
(en)
*
|
2001-05-07 |
2002-12-26 |
Allergan Sales, Inc. |
Disinfecting and solubilizing steroid compositions
|
|
US20040152664A1
(en)
*
|
1998-09-02 |
2004-08-05 |
Allergan, Inc. |
Prednisolone compositions
|
|
AU772204B2
(en)
*
|
1999-01-21 |
2004-04-22 |
Bristol-Myers Squibb Company |
Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-beta-cyclodextrin or 2-hydroxypropyl-beta-cyclodextrin and method
|
|
GB9913932D0
(en)
|
1999-06-15 |
1999-08-18 |
Pfizer Ltd |
Purine derivatives
|
|
GB9915231D0
(en)
*
|
1999-06-29 |
1999-09-01 |
Pfizer Ltd |
Pharmaceutical complex
|
|
CA2315614C
(en)
|
1999-07-29 |
2004-11-02 |
Pfizer Inc. |
Pyrazoles
|
|
DE19939662A1
(de)
|
1999-08-20 |
2001-02-22 |
Stockhausen Chem Fab Gmbh |
Wasserabsorbierende Polymere mit Hohlraumverbindungen, Verfahren zur deren Herstellung und deren Verwendung
|
|
GB9921958D0
(en)
|
1999-09-16 |
1999-11-17 |
Pharmacia & Upjohn Spa |
Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins
|
|
GB9921954D0
(en)
*
|
1999-09-16 |
1999-11-17 |
Pharmacia & Upjohn Spa |
Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
|
|
RU2163120C1
(ru)
*
|
1999-10-12 |
2001-02-20 |
Новосибирский медицинский институт |
Конъюгат изониазид-декстран и его применение в качестве противотуберкулезного препарата
|
|
GB9924363D0
(en)
|
1999-10-14 |
1999-12-15 |
Pfizer Central Res |
Purine derivatives
|
|
GB9924361D0
(en)
|
1999-10-14 |
1999-12-15 |
Pfizer Ltd |
Purine derivatives
|
|
AU777449C
(en)
*
|
1999-12-28 |
2007-03-15 |
Kimberly-Clark Worldwide, Inc. |
Superabsorbent polymers
|
|
US6677256B1
(en)
|
1999-12-28 |
2004-01-13 |
Kimberly-Clark Worldwide, Inc. |
Fibrous materials containing activating agents for making superabsorbent polymers
|
|
US6689378B1
(en)
|
1999-12-28 |
2004-02-10 |
Kimberly-Clark Worldwide, Inc. |
Cyclodextrins covalently bound to polysaccharides
|
|
SK282717B6
(sk)
*
|
2000-03-10 |
2002-11-06 |
�Stav Experiment�Lnej Farmakol�Gie Sav |
Spôsob prípravy ultravysokomolekulových hyalurónanov
|
|
US20020022627A1
(en)
*
|
2000-03-31 |
2002-02-21 |
Dannenberg Andrew J. |
Inhibition of cyclooxygenase-2activity
|
|
WO2001083564A1
(en)
*
|
2000-04-28 |
2001-11-08 |
University College Dublin |
Amphiphilic macrocyclic derivatives and their analogues
|
|
DE60136926D1
(de)
*
|
2000-05-02 |
2009-01-22 |
Theravance Inc |
Zusammensetzung die eine zyklodextrin und ein glykopeptid-antibiotikum enthält
|
|
US6667314B2
(en)
|
2000-05-26 |
2003-12-23 |
Pfizer, Inc. |
Tropane derivatives useful in therapy
|
|
EP1526134B1
(de)
|
2000-05-26 |
2008-09-03 |
Pfizer Limited |
Triazolyltropanderivate als ccr5-modulatoren
|
|
US6753322B2
(en)
|
2000-06-06 |
2004-06-22 |
Pfizer Inc |
2-aminocarbonyl-9H-purine derivatives
|
|
US6921753B2
(en)
|
2000-06-27 |
2005-07-26 |
Pfizer Inc |
Purine derivatives
|
|
US6468989B1
(en)
|
2000-07-13 |
2002-10-22 |
Dow Pharmaceutical Sciences |
Gel compositions containing metronidazole
|
|
US6420557B1
(en)
|
2000-07-28 |
2002-07-16 |
Pfizer Inc. |
Crystalline therapeutic agent
|
|
US7198801B2
(en)
*
|
2000-08-03 |
2007-04-03 |
Antares Pharma Ipl Ag |
Formulations for transdermal or transmucosal application
|
|
US20040198706A1
(en)
*
|
2003-03-11 |
2004-10-07 |
Carrara Dario Norberto R. |
Methods and formulations for transdermal or transmucosal application of active agents
|
|
CA2418135C
(en)
*
|
2000-08-03 |
2011-09-20 |
Antares Pharma Ipl Ag |
Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels
|
|
US8980290B2
(en)
|
2000-08-03 |
2015-03-17 |
Antares Pharma Ipl Ag |
Transdermal compositions for anticholinergic agents
|
|
US20070225379A1
(en)
*
|
2001-08-03 |
2007-09-27 |
Carrara Dario Norberto R |
Transdermal delivery of systemically active central nervous system drugs
|
|
PE20020300A1
(es)
*
|
2000-08-22 |
2002-05-10 |
Pharmacia Corp |
Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
|
|
GB0022695D0
(en)
|
2000-09-15 |
2000-11-01 |
Pfizer Ltd |
Purine Derivatives
|
|
AR031135A1
(es)
|
2000-10-10 |
2003-09-10 |
Upjohn Co |
Composiciones de antibiotico topico para el tratamiento de infecciones oculares
|
|
US6548508B2
(en)
|
2000-10-20 |
2003-04-15 |
Pfizer, Inc. |
Use of PDE V inhibitors for improved fecundity in mammals
|
|
CA2430669C
(en)
*
|
2000-11-30 |
2011-06-14 |
The Children's Medical Center Corporation |
Synthesis of 3-amino-thalidomide and its enantiomers
|
|
RU2288921C2
(ru)
*
|
2000-12-19 |
2006-12-10 |
Калифорниа Инститьют оф Текнолоджи |
Композиции, содержащие комплексы включения
|
|
US6566556B2
(en)
*
|
2000-12-19 |
2003-05-20 |
Nippon Shokubai Co., Ltd. |
Method for production of alkanolamine and apparatus therefor
|
|
WO2002055562A2
(en)
*
|
2001-01-11 |
2002-07-18 |
Eastman Chem Co |
Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials
|
|
US20020146409A1
(en)
*
|
2001-01-30 |
2002-10-10 |
Herring Steven W. |
Methods for stabilizing lyophilized blood proteins
|
|
IL141647A0
(en)
*
|
2001-02-26 |
2002-03-10 |
Yeda Res & Dev |
Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
|
|
US7034013B2
(en)
*
|
2001-03-20 |
2006-04-25 |
Cydex, Inc. |
Formulations containing propofol and a sulfoalkyl ether cyclodextrin
|
|
SI1762567T1
(sl)
|
2001-04-10 |
2012-08-31 |
Pfizer |
Derivati pirazola za zdravljenje HIV-a
|
|
BR0102252B1
(pt)
*
|
2001-04-10 |
2013-10-22 |
|
Sistema de liberação controlada para antagonista do receptor AT1 da angiotensina II, composição farmacêutica e seu uso
|
|
AP2003002900A0
(en)
*
|
2001-05-01 |
2003-12-31 |
Pfizer Prod Inc |
Method for manufacturing a low dose pharmaceutical composition
|
|
UY27304A1
(es)
|
2001-05-24 |
2002-12-31 |
Avanir Pharmaceuticals |
Inhibidores del factor inhibidor de la migración de los macrófagos y métodos para su identificación
|
|
US7595378B2
(en)
|
2001-06-13 |
2009-09-29 |
Genmab A/S |
Human monoclonal antibodies to epidermal growth factor receptor (EGFR)
|
|
EP1269994A3
(de)
*
|
2001-06-22 |
2003-02-12 |
Pfizer Products Inc. |
Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten
|
|
GB0116453D0
(en)
|
2001-07-05 |
2001-08-29 |
Imp College Innovations Ltd |
Method
|
|
US6653339B2
(en)
|
2001-08-15 |
2003-11-25 |
Pfizer Inc. |
Method of treating irritable bowel syndrome
|
|
US7141540B2
(en)
*
|
2001-11-30 |
2006-11-28 |
Genta Salus Llc |
Cyclodextrin grafted biocompatible amphilphilic polymer and methods of preparation and use thereof
|
|
CN100391464C
(zh)
*
|
2001-12-03 |
2008-06-04 |
诺瓦西股份有限公司 |
含活性维生素d化合物的药物组合物
|
|
GB0129273D0
(en)
|
2001-12-06 |
2002-01-23 |
Pfizer Ltd |
Crystalline drug form
|
|
US6881726B2
(en)
|
2001-12-24 |
2005-04-19 |
Dow Pharmaceutical Sciences |
Aqueous compositions containing metronidazole
|
|
BR0307332A
(pt)
|
2002-02-01 |
2004-12-07 |
Pfizer Prod Inc |
Formas de dosagem farmacêuticas de liberação controlada de um inibidor da proteìna de transferência do éster de colesterol
|
|
US6756392B2
(en)
|
2002-02-11 |
2004-06-29 |
Pfizer Inc |
Nicotinamide derivatives useful as PDE4 inhibitors
|
|
MXPA04007737A
(es)
|
2002-02-11 |
2004-10-15 |
Pfizer |
Derivados de nicotinamida utiles como inhibidores de fosfodesterasas 4.
|
|
US20030164219A1
(en)
*
|
2002-02-20 |
2003-09-04 |
Joerg Brahm |
Headliner/duct assembly and welding process therefor
|
|
JP2005521690A
(ja)
*
|
2002-02-22 |
2005-07-21 |
ファルマシア・コーポレーション |
ゴム系を含む眼科用製剤
|
|
EP1478404A1
(de)
*
|
2002-02-22 |
2004-11-24 |
Pharmacia Corporation |
Ophthalmische antibiotische arzneimittel formulierungen enthaltend eine cyclodextrin verbindung und cetylpyridiniumchlorid
|
|
GB0207104D0
(en)
|
2002-03-26 |
2002-05-08 |
Pfizer Ltd |
Stable hydrate of a muscarinic receptor antagonist
|
|
KR100451485B1
(ko)
*
|
2002-03-28 |
2004-10-06 |
주식회사종근당 |
푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
|
|
US6855724B2
(en)
|
2002-04-08 |
2005-02-15 |
Agouron Pharmaceuticals, Inc. |
Tropane derivatives useful in therapy
|
|
DE10215942A1
(de)
*
|
2002-04-11 |
2003-10-23 |
Bayer Ag |
Wässrige Formulierungen von (2-Hydroxymethyl-indanyl-4-oxy)-phenyl-4,4,4-trifluorbutan-1-sulfonat
|
|
GB0209022D0
(en)
|
2002-04-19 |
2002-05-29 |
Imp College Innovations Ltd |
Compounds
|
|
US6869939B2
(en)
*
|
2002-05-04 |
2005-03-22 |
Cydex, Inc. |
Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
|
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
US7323479B2
(en)
*
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
|
USRE48890E1
(en)
|
2002-05-17 |
2022-01-11 |
Celgene Corporation |
Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
|
|
EP1556033A4
(de)
*
|
2002-05-17 |
2006-05-31 |
Celgene Corp |
Verfahren und zusammensetzungen mit selektiven cytokin-hemmenden arzneimitteln zur behandlung und versorgung von krebs und anderen erkrankungen
|
|
DK1505973T3
(da)
|
2002-05-17 |
2010-05-31 |
Celgene Corp |
Kombinationer til behandling af multipelt myelom
|
|
US20100129363A1
(en)
*
|
2002-05-17 |
2010-05-27 |
Zeldis Jerome B |
Methods and compositions using pde4 inhibitors for the treatment and management of cancers
|
|
US7393862B2
(en)
*
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
|
US6818662B2
(en)
*
|
2002-05-28 |
2004-11-16 |
Taisho Pharmaceutical Co., Ltd. |
Pharmaceutical composition
|
|
NZ537995A
(en)
*
|
2002-08-20 |
2007-11-30 |
Bristol Myers Squibb Co |
Inclusion complex of aripiprazole in a substituted b-cyclodextrin
|
|
GB0219961D0
(en)
|
2002-08-28 |
2002-10-02 |
Pfizer Ltd |
Oxytocin inhibitors
|
|
AU2003272260A1
(en)
*
|
2002-09-09 |
2004-03-29 |
Josef Pitha |
Verifiable absorption drug delivery form based on cyclodextrins
|
|
GB0221169D0
(en)
|
2002-09-12 |
2002-10-23 |
Univ Bath |
Crystal
|
|
MXPA05002728A
(es)
*
|
2002-09-13 |
2005-07-25 |
Cydex Inc |
Capsulas que contienen composiciones de relleno acuoso estabilizadas con ciclodextrina derivada.
|
|
US20040053895A1
(en)
*
|
2002-09-18 |
2004-03-18 |
Bone Care International, Inc. |
Multi-use vessels for vitamin D formulations
|
|
US7148211B2
(en)
*
|
2002-09-18 |
2006-12-12 |
Genzyme Corporation |
Formulation for lipophilic agents
|
|
US20040058895A1
(en)
*
|
2002-09-18 |
2004-03-25 |
Bone Care International, Inc. |
Multi-use vessels for vitamin D formulations
|
|
US7230025B2
(en)
|
2002-09-26 |
2007-06-12 |
Pfizer, Inc. |
Pyrazole derivatives
|
|
US6933312B2
(en)
|
2002-10-07 |
2005-08-23 |
Agouron Pharmaceuticals, Inc. |
Pyrazole derivatives
|
|
US7189740B2
(en)
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
|
US8404717B2
(en)
*
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
|
MXPA05003889A
(es)
*
|
2002-10-15 |
2005-06-22 |
Celgene Corp |
Farmacos inhibidores de citosina selectiva para tratar sindrome mielodisplastico.
|
|
US8404716B2
(en)
*
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
|
EP1900369A1
(de)
|
2002-10-15 |
2008-03-19 |
Celgene Corporation |
Verfahren zur Verwendung von und Zusammensetzungen mit immunmodulatorischen Verbindungen für die Therapie und Behandlung des myelodysplastischen Syndroms
|
|
US11116782B2
(en)
|
2002-10-15 |
2021-09-14 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
|
US20050203142A1
(en)
*
|
2002-10-24 |
2005-09-15 |
Zeldis Jerome B. |
Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain
|
|
US20040087558A1
(en)
|
2002-10-24 |
2004-05-06 |
Zeldis Jerome B. |
Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment, modification and management of pain
|
|
US7001893B2
(en)
*
|
2002-10-28 |
2006-02-21 |
Council Of Scientific And Industrial Research |
Inclusion complex of Rifampicin, an anti-tubercular drug, with β-cyclodextrin or 2-hydroxypropyl β-cyclodextrin and a process thereof
|
|
US7563810B2
(en)
|
2002-11-06 |
2009-07-21 |
Celgene Corporation |
Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
|
|
WO2004043378A2
(en)
|
2002-11-06 |
2004-05-27 |
Celgene Corporation |
Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
|
|
US20050026877A1
(en)
*
|
2002-12-03 |
2005-02-03 |
Novacea, Inc. |
Pharmaceutical compositions comprising active vitamin D compounds
|
|
US7323462B2
(en)
|
2002-12-10 |
2008-01-29 |
Pfizer Inc. |
Morpholine dopamine agonists
|
|
CA2451267A1
(en)
|
2002-12-13 |
2004-06-13 |
Warner-Lambert Company Llc |
Pharmaceutical uses for alpha2delta ligands
|
|
PT1572173E
(pt)
|
2002-12-13 |
2010-05-10 |
Warner Lambert Co |
Ligando alfa-2-delta para tratar sintomas do tracto urinário inferior
|
|
US7166575B2
(en)
*
|
2002-12-17 |
2007-01-23 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
|
|
US7229966B2
(en)
*
|
2002-12-17 |
2007-06-12 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
|
|
JP2006516262A
(ja)
*
|
2002-12-17 |
2006-06-29 |
ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド |
Y2受容体結合ペプチドの粘膜送達促進のための組成物および方法ならびに肥満症の治療法および予防法
|
|
US7186692B2
(en)
*
|
2002-12-17 |
2007-03-06 |
Nastech Pharmaceutical Company Inc. |
Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
|
|
DK1594434T3
(da)
*
|
2003-01-14 |
2017-01-02 |
Yeda Res & Dev Company Ltd At The Weizmann Inst Of Science |
Parenterale formuleringer af peptide til behandling af systemisk lupus erythematosus
|
|
NZ541659A
(en)
*
|
2003-01-14 |
2007-05-31 |
Teva Pharma |
Pharmaceutical composition comprising with a pH between 4 and 9 to treat SLE comprising an aqueous carrier, a pharmaceutically acceptable salt of a peptide and a substituted beta-cyclodextrin
|
|
EP1460064A1
(de)
|
2003-03-14 |
2004-09-22 |
Pfizer Limited |
Indole-2-carboxamide als beta-2 Agonisten
|
|
CL2004000826A1
(es)
|
2003-04-25 |
2005-03-04 |
Pfizer |
Uso de un agonista para el receptor 5-ht2c para preparar un medicamento util en el tratamiento de la incontinencia urinaria provocada por estres, con la condicion de que el agonista no sea 1-[6-cloro-5-(trifluorometil)-2-piridinil]piperazina (org-129
|
|
US7157446B2
(en)
*
|
2003-05-02 |
2007-01-02 |
Bristol Myers Squibb Company |
Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
|
|
US7268147B2
(en)
|
2003-05-15 |
2007-09-11 |
Pfizer Inc |
Compounds useful for the treatment of diseases
|
|
US20050020546A1
(en)
*
|
2003-06-11 |
2005-01-27 |
Novacea, Inc. |
Pharmaceutical compositions comprising active vitamin D compounds
|
|
ES2905724T3
(es)
|
2003-06-13 |
2022-04-11 |
Alnylam Europe Ag |
Acido ribonucleico bicatenario con elevada eficacia en un organismo
|
|
PL1664036T3
(pl)
|
2003-09-03 |
2012-04-30 |
Pfizer |
Związki benzimidazolonu wykazujące działanie agonistyczne względem receptora 5-ht4
|
|
ATE450535T1
(de)
|
2003-09-03 |
2009-12-15 |
Glaxo Group Ltd |
Neues verfahren zur herstellung von pleuromutilinderivaten
|
|
US7220772B2
(en)
|
2003-09-05 |
2007-05-22 |
Pfizer, Inc. |
Pyrazole derivatives
|
|
WO2005023308A1
(en)
*
|
2003-09-05 |
2005-03-17 |
Maxygen Holdings Ltd. |
Formulations of vitamin k-dependent polypeptides and sulfoalkyl ether cycloextrins
|
|
ATE449633T1
(de)
|
2003-09-12 |
2009-12-15 |
Pfizer |
Kombinationen aus alpha-2-delta liganden und serotonin / noradrenalin-wiederaufnahmehemmern
|
|
ES2295924T3
(es)
|
2003-10-03 |
2008-04-16 |
Pfizer, Inc. |
Derivados de tropano imidazopirina sustituidos con actividad antagonista de los receptores ccr5 para el tratamiento de vih y de la inflamacion.
|
|
CA2538856C
(en)
*
|
2003-10-10 |
2010-06-29 |
Antares Pharma Ipl Ag |
Transdermal pharmaceutical formulation for minimizing skin residues
|
|
TW200517114A
(en)
|
2003-10-15 |
2005-06-01 |
Combinatorx Inc |
Methods and reagents for the treatment of immunoinflammatory disorders
|
|
US7612096B2
(en)
*
|
2003-10-23 |
2009-11-03 |
Celgene Corporation |
Methods for treatment, modification and management of radiculopathy using 1-oxo-2-(2,6-dioxopiperidin-3yl)-4-aminoisoindoline
|
|
US7129042B2
(en)
*
|
2003-11-03 |
2006-10-31 |
Diagnostic Hybrids, Inc. |
Compositions and methods for detecting severe acute respiratory syndrome coronavirus
|
|
EA200600921A1
(ru)
|
2003-11-06 |
2006-10-27 |
Селджин Корпорейшн |
Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
|
|
JP2007512337A
(ja)
|
2003-11-21 |
2007-05-17 |
コンビナトアールエックス インコーポレーティッド |
炎症性障害の治療のための方法および試薬
|
|
ZA200604579B
(en)
*
|
2003-12-08 |
2007-10-31 |
Univ Arizona |
Synergistic anti-cancer compositions
|
|
PT1691811E
(pt)
|
2003-12-11 |
2014-10-30 |
Sunovion Pharmaceuticals Inc |
Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
|
|
US20070020299A1
(en)
*
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
|
|
WO2005065435A2
(en)
*
|
2003-12-31 |
2005-07-21 |
Cydex, Inc. Et Al. |
Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
|
|
US20070020298A1
(en)
*
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
|
|
US20070020196A1
(en)
*
|
2003-12-31 |
2007-01-25 |
Pipkin James D |
Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
|
|
CA2553789C
(en)
|
2004-01-22 |
2011-07-19 |
Pfizer Inc. |
Sulfonamide derivatives for the treatment of diseases
|
|
ME00557A
(en)
|
2004-01-22 |
2011-12-20 |
|
Sulfonamide derivatives for the treatment of diseases
|
|
EP1708718A1
(de)
|
2004-01-22 |
2006-10-11 |
Pfizer Limited |
Triazol-derivate zur hemmung der vasopressing-antagonistischen aktivität
|
|
CA2552356C
(en)
|
2004-02-24 |
2013-11-19 |
The General Hospital Corporation |
Catalytic radiofluorination
|
|
ATE446581T1
(de)
*
|
2004-03-12 |
2009-11-15 |
Trinity College Dublin |
Magnetoresistives medium
|
|
US7629358B2
(en)
|
2004-03-17 |
2009-12-08 |
Pfizer Inc |
Compounds useful for the treatment of diseases
|
|
CA2560510C
(en)
|
2004-03-18 |
2009-10-13 |
Pfizer Inc. |
N-(1-arylpyrazol-4yl) sulfonamides and their use as parasiticides
|
|
AU2005226649B2
(en)
|
2004-03-22 |
2010-04-29 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders
|
|
US7538141B2
(en)
|
2004-03-23 |
2009-05-26 |
Alan Daniel Brown |
Compounds for the treatment of diseases
|
|
PL1730103T3
(pl)
|
2004-03-23 |
2010-10-29 |
Pfizer |
Pochodne formamidu użyteczne jako adrenoreceptor
|
|
US20080213213A1
(en)
*
|
2004-04-14 |
2008-09-04 |
Zeldis Jerome B |
Method For the Treatment of Myelodysplastic Syndromes Using (+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione
|
|
JP2007532641A
(ja)
*
|
2004-04-14 |
2007-11-15 |
セルジーン・コーポレーション |
脊髄形成異常症候群の治療及び管理のための免疫調節化合物の使用法、及びそれを含む組成物
|
|
ATE494298T1
(de)
|
2004-04-15 |
2011-01-15 |
Proteolix Inc |
Verbindungen zur proteasomenzymhemmung
|
|
US20050234018A1
(en)
*
|
2004-04-15 |
2005-10-20 |
Allergan, Inc. |
Drug delivery to the back of the eye
|
|
US8198270B2
(en)
*
|
2004-04-15 |
2012-06-12 |
Onyx Therapeutics, Inc. |
Compounds for proteasome enzyme inhibition
|
|
BRPI0510119A
(pt)
|
2004-04-23 |
2007-09-25 |
Cydex Inc |
formulação para dpi contendo sulfoaquil éter de ciclodextrina
|
|
AU2005323437B2
(en)
|
2004-04-30 |
2011-10-06 |
Alnylam Pharmaceuticals, Inc. |
Oligonucleotides comprising a C5-modified pyrimidine
|
|
AP2006003771A0
(en)
|
2004-04-30 |
2006-10-31 |
Warner Lambert Co |
Substituted morpholine compounds for the treatmentof central nervous system disorders
|
|
BRPI0509592A
(pt)
*
|
2004-05-06 |
2007-09-25 |
Cydex Inc |
formulações de sabor mascarado, contendo sertralina e ciclodextrina de éter de sulfoalquila
|
|
US7456164B2
(en)
|
2004-05-07 |
2008-11-25 |
Pfizer, Inc |
3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
|
|
SI2030981T1
(sl)
*
|
2004-05-10 |
2014-11-28 |
Onyx Therapeutics, Inc. |
Spojine za inhibiranje proteasomskega encima
|
|
EP1595881A1
(de)
|
2004-05-12 |
2005-11-16 |
Pfizer Limited |
Tetrahydronaphthyridin-Derivate, verwendbar als Histamin H3 Rezeptor-Liganden
|
|
US7737163B2
(en)
|
2004-06-15 |
2010-06-15 |
Pfizer Inc. |
Benzimidazolone carboxylic acid derivatives
|
|
EA200801607A1
(ru)
|
2004-06-15 |
2008-10-30 |
Пфайзер Инк. |
Производные бензимидазолонкарбоновой кислоты
|
|
WO2006007412A2
(en)
*
|
2004-06-16 |
2006-01-19 |
Nastech Pharmaceutical Company Inc. |
Peptide yy formulations having increased stability and resistance to microbial agents
|
|
KR101195351B1
(ko)
|
2004-06-17 |
2012-10-29 |
인피니티 디스커버리, 인코포레이티드 |
Bcl 단백질과 결합 파트너와의 상호작용을 억제하는화합물 및 방법
|
|
AU2005273612B2
(en)
|
2004-08-12 |
2010-10-14 |
Pfizer Inc. |
Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors
|
|
JP4242911B2
(ja)
|
2004-08-26 |
2009-03-25 |
ファイザー・インク |
プロテインキナーゼ阻害薬としてのエナンチオピュアなアミノヘテロアリール化合物
|
|
NZ554068A
(en)
*
|
2004-09-03 |
2009-07-31 |
Celgene Corp |
Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindo-lines
|
|
US20070190070A1
(en)
*
|
2004-09-03 |
2007-08-16 |
Zeldis Jerome B |
Methods of using and compositions comprising selective cytokine inhibitory drugs for the treatment and management of disorders of the central nervous system
|
|
US8080675B2
(en)
|
2004-09-21 |
2011-12-20 |
Marshall Edwards, Inc. |
Chroman derivatives, medicaments and use in therapy
|
|
EP2436680B1
(de)
|
2004-09-21 |
2016-05-18 |
Marshall Edwards, Inc. |
Chromanderivate, Medikamente und Anwendung in der Therapie
|
|
CN101056868B
(zh)
|
2004-09-21 |
2012-05-02 |
马休爱德华兹股份有限公司 |
取代的苯并二氢吡喃衍生物、药物及其在治疗中的应用
|
|
US20060078955A1
(en)
*
|
2004-10-13 |
2006-04-13 |
Lin-Zhi International |
Method for retrieving delta9-THC from oral fluid
|
|
WO2006046933A1
(en)
*
|
2004-10-26 |
2006-05-04 |
Viktor Olexandrovych Rybchuk |
Sedative and spasmolytic medicinal agent and method for the production thereof (variants)
|
|
EP1811992A2
(de)
*
|
2004-10-28 |
2007-08-01 |
Celgene Corporation |
Verfahren und zusammensetzungen unter verwendung von pde4-modulatoren zur behandlung und versorgung von verletzungen des zentralen nervensystems
|
|
CA2586179C
(en)
|
2004-11-02 |
2011-02-08 |
Pfizer Inc. |
Sulfonyl benzimidazole derivatives
|
|
US9120774B2
(en)
|
2004-11-03 |
2015-09-01 |
University Of Kansas |
Novobiocin analogues having modified sugar moieties
|
|
GT200500317A
(es)
*
|
2004-11-05 |
2006-10-27 |
|
Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
|
|
US20060105045A1
(en)
*
|
2004-11-08 |
2006-05-18 |
Buchanan Charles M |
Cyclodextrin solubilizers for liquid and semi-solid formulations
|
|
WO2006052922A2
(en)
*
|
2004-11-08 |
2006-05-18 |
Eastman Chemical Company |
Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds
|
|
EP2261236B1
(de)
*
|
2004-12-07 |
2015-07-15 |
Onyx Therapeutics, Inc. |
Zusammensetzung zur Proteasomhemmung
|
|
US20060128654A1
(en)
*
|
2004-12-10 |
2006-06-15 |
Chunlin Tang |
Pharmaceutical formulation of cytidine analogs and derivatives
|
|
US20060128653A1
(en)
*
|
2004-12-10 |
2006-06-15 |
Chunlin Tang |
Pharmaceutical formulation of decitabine
|
|
DE102004060927B3
(de)
*
|
2004-12-17 |
2006-02-16 |
Schwan-Stabilo Schwanhäusser Gmbh & Co. Kg |
Behälter für mindestens einen länglichen Gegenstand
|
|
EP1674098A1
(de)
|
2004-12-23 |
2006-06-28 |
Schering Aktiengesellschaft |
Stabile, unbedenkliche parenterale Formulierungen von hochreaktiven organischen Arzneimitteln mit niedriger oder keiner wässrigen Löslichkeit
|
|
EP1853231A2
(de)
*
|
2005-02-16 |
2007-11-14 |
Alza Corporation |
Vorrichtung und verfahren zur transdermalen zuführung von agentien auf erythropoetin-basis
|
|
BRPI0608381A2
(pt)
*
|
2005-02-18 |
2009-12-29 |
Surface Logix Inc |
compostos aprimorados farmacocineticamente
|
|
JP2008530246A
(ja)
*
|
2005-02-18 |
2008-08-07 |
サーフェイス ロジックス,インコーポレイティド |
機能性残基又は官能基を含む薬物動態学的に改善された化合物、及び上述の化合物を含む医薬組成物の製造方法
|
|
US8703099B2
(en)
|
2005-02-24 |
2014-04-22 |
Dr Pharma Nova, Llc |
Registry method and control system for DEA schedule II-V medicines
|
|
EA200701745A1
(ru)
|
2005-03-17 |
2008-06-30 |
Пфайзер, Инк. |
Циклопропанкарбоксамидные производные
|
|
JP2008533192A
(ja)
|
2005-03-21 |
2008-08-21 |
ファイザー・リミテッド |
オキシトシンアンタゴニストとしての置換されたトリアゾール誘導体
|
|
EP2484382A1
(de)
|
2005-03-30 |
2012-08-08 |
Schering Corporation |
Medikament enthaltend einem Phosphodiesterase IV Inhibitor in einer zur Inhalation geeigneten Form
|
|
DK1871353T3
(da)
*
|
2005-04-15 |
2011-04-04 |
Einstein Coll Med |
Vitamin k til forebyggelse eller behandling af hududslæt sekundært til anti-EGFR-terapi
|
|
JP5422203B2
(ja)
|
2005-04-19 |
2014-02-19 |
キングス カレッジ ロンドン |
使用
|
|
WO2007124250A2
(en)
|
2006-04-21 |
2007-11-01 |
Antares Pharma Ipl Ag |
Methods of treating hot flashes with formulations for transdermal or transmucosal application
|
|
BRPI0609952A2
(pt)
*
|
2005-04-24 |
2010-05-11 |
Wyeth Corp |
métodos para modular a função da bexiga
|
|
EA200702235A1
(ru)
|
2005-05-04 |
2008-04-28 |
Пфайзер Лимитед |
Производные 2-амидо-6-амино-8-оксопурина в качестве модуляторов toll-подобных рецепторов для лечения рака и вирусных инфекций, таких как гепатит с
|
|
US8669236B2
(en)
*
|
2005-05-12 |
2014-03-11 |
The General Hospital Corporation |
Biotinylated compositions
|
|
US20060270707A1
(en)
*
|
2005-05-24 |
2006-11-30 |
Zeldis Jerome B |
Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
|
|
WO2006125642A1
(en)
|
2005-05-27 |
2006-11-30 |
Antares Pharma Ipl Ag |
Methods and apparatus for transdermal or transmucosal application of testosterone
|
|
RU2008101420A
(ru)
*
|
2005-06-13 |
2009-07-20 |
Карджилл, Инкорпорейтед (Us) |
Циклодекстриновые комплексы включения и способы их получения
|
|
US20090029020A1
(en)
*
|
2005-06-13 |
2009-01-29 |
Cargill, Incorporated |
Cyclodextrin inclusion complexes and methods of preparing same
|
|
JPWO2006134877A1
(ja)
*
|
2005-06-13 |
2009-01-08 |
武田薬品工業株式会社 |
注射剤
|
|
US20080176865A1
(en)
*
|
2005-06-15 |
2008-07-24 |
Pfizer Limited |
Substituted arylpyrazoles
|
|
US7645786B2
(en)
|
2005-06-15 |
2010-01-12 |
Pfizer Inc. |
Substituted arylpyrazoles
|
|
EP1893581B1
(de)
|
2005-06-15 |
2010-01-27 |
Pfizer Limited |
Substituierte arylpyrazole zur verwendung gegen parasiten
|
|
US20080146643A1
(en)
*
|
2005-06-15 |
2008-06-19 |
Pfizer Limited |
Combination
|
|
US20060287301A1
(en)
*
|
2005-06-17 |
2006-12-21 |
Mcnair Douglas |
Novel formulations for phenothiazines, including fluphenazine and its derivatives
|
|
PL1907373T3
(pl)
*
|
2005-06-30 |
2013-05-31 |
Celgene Corp |
Sposób wytwarzania związków 4-amino-2-(2,6-diokso-piperydyn-3-ylo)izoindolino-1,3-dionu
|
|
US20070010486A1
(en)
*
|
2005-07-06 |
2007-01-11 |
Jeff Schwegman |
Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
|
|
US20070010485A1
(en)
*
|
2005-07-06 |
2007-01-11 |
Jeff Schwegman |
Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
|
|
WO2007008496A1
(en)
*
|
2005-07-06 |
2007-01-18 |
Kanisa Pharmaceuticals, Inc. |
Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
|
|
US20070010466A1
(en)
*
|
2005-07-06 |
2007-01-11 |
Branimir Sikic |
Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
|
|
US20070009532A1
(en)
*
|
2005-07-06 |
2007-01-11 |
Branimir Sikic |
Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar
|
|
US20070010487A1
(en)
*
|
2005-07-06 |
2007-01-11 |
Jeff Schwegman |
Chemotherapeutic formulations of zosuquidar trihydrochloride and modified cyclodextrins
|
|
AR054849A1
(es)
*
|
2005-07-26 |
2007-07-18 |
Wyeth Corp |
Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
|
|
US20070191306A1
(en)
*
|
2005-08-17 |
2007-08-16 |
Bristol-Myers Squibb Company |
FACTOR Xa INHIBITOR FORMULATION AND METHOD
|
|
CA2822094C
(en)
|
2005-08-31 |
2015-10-27 |
Celgene Corporation |
Isoindole-imide compounds and compositions comprising and methods of using the same
|
|
US8580814B2
(en)
*
|
2006-04-03 |
2013-11-12 |
Sunesis Pharmaceuticals, Inc. |
Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
|
|
US20080138295A1
(en)
*
|
2005-09-12 |
2008-06-12 |
Celgene Coporation |
Bechet's disease using cyclopropyl-N-carboxamide
|
|
US20070066512A1
(en)
|
2005-09-12 |
2007-03-22 |
Dominique Verhelle |
Methods and compositions using immunomodulatory compounds for the treatment of disorders associated with low plasma leptin levels
|
|
US7744904B1
(en)
*
|
2005-09-26 |
2010-06-29 |
B.B. Scientific L.L.C. |
Stabilization of Clostridium botulinum neurotoxin complex
|
|
AU2013200204B9
(en)
*
|
2005-09-30 |
2015-03-05 |
Lundbeck Llc |
Novel parenteral carbamazepine formulation
|
|
US20100204178A1
(en)
|
2006-10-02 |
2010-08-12 |
James Cloyd |
Novel parenteral carbamazepine formulation
|
|
WO2007041524A2
(en)
*
|
2005-09-30 |
2007-04-12 |
Ovation Pharmaceuticals, Inc. |
Novel parenteral carbamazepine formulation
|
|
SI2952197T1
(sl)
|
2005-10-26 |
2017-09-29 |
Cydex Pharmaceuticals, Inc. |
Sestavki sulfoalkil eter ciklodekstrina in metode priprave le-tega
|
|
AU2011204957B2
(en)
*
|
2005-10-26 |
2013-12-05 |
Cydex Pharmaceuticals, Inc |
Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
|
|
RU2417103C2
(ru)
*
|
2005-10-26 |
2011-04-27 |
Сайдекс Фармасьютикалз, Инк. |
Композиции простого сульфоалкилового эфира циклодекстрина и способы их получения
|
|
CN100503647C
(zh)
|
2005-11-02 |
2009-06-24 |
南京师范大学 |
羟丙基-磺丁基-β-环糊精及其制备方法、分析方法以及在药学上的应用
|
|
EP2623113B1
(de)
|
2005-11-09 |
2017-05-31 |
Onyx Therapeutics, Inc. |
Verbindung zur Enzymhemmung
|
|
US20070111965A1
(en)
*
|
2005-11-15 |
2007-05-17 |
Kipp James E |
Compositions comprising lipoxygenase inhibitors and cyclodextrin
|
|
WO2007062403A2
(en)
*
|
2005-11-28 |
2007-05-31 |
Vernon D Rowe |
Compositions useful for reducing nephrotoxicity and methods of use thereof
|
|
US7658913B2
(en)
*
|
2005-11-28 |
2010-02-09 |
Verrow Pharmaceuticals, Inc. |
Compositions useful for reducing nephrotoxicity and methods of use thereof
|
|
ES2812250T3
(es)
|
2005-11-28 |
2021-03-16 |
Marinus Pharmaceuticals Inc |
Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas
|
|
US20070135586A1
(en)
*
|
2005-12-09 |
2007-06-14 |
Shreyas Chakravarti |
Polyamide blend compositions formed article and process thereof
|
|
US20070232537A1
(en)
*
|
2005-12-19 |
2007-10-04 |
Nastech Pharmaceutical Company Inc. |
Intranasal pyy formulations with improved transmucosal pharmacokinetics
|
|
US20070249572A1
(en)
*
|
2005-12-20 |
2007-10-25 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids
|
|
US20070197486A1
(en)
*
|
2005-12-20 |
2007-08-23 |
Verus Pharmaceuticals, Inc. |
Methods and systems for the delivery of corticosteroids
|
|
NL2000323C2
(nl)
|
2005-12-20 |
2007-11-20 |
Pfizer Ltd |
Pyrimidine-derivaten.
|
|
US20070178049A1
(en)
*
|
2005-12-20 |
2007-08-02 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
|
|
US20070160542A1
(en)
*
|
2005-12-20 |
2007-07-12 |
Verus Pharmaceuticals, Inc. |
Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
|
|
US20070185066A1
(en)
*
|
2005-12-20 |
2007-08-09 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids
|
|
US20070141684A1
(en)
|
2005-12-21 |
2007-06-21 |
Pfizer Inc |
Preparation of gamma-amino acids having affinity for the alpha-2-delta protein
|
|
US20070155791A1
(en)
*
|
2005-12-29 |
2007-07-05 |
Zeldis Jerome B |
Methods for treating cutaneous lupus using aminoisoindoline compounds
|
|
GB0600406D0
(en)
|
2006-01-10 |
2006-02-15 |
Univ Bath |
Crystal
|
|
GB0600928D0
(en)
|
2006-01-17 |
2006-02-22 |
Novacta Biosystems Ltd |
Improvements relating to lantibiotics
|
|
CA2642577A1
(en)
*
|
2006-02-15 |
2007-08-23 |
Tika Lakemedel Ab |
Methods of manufacturing corticosteroid solutions
|
|
JP2009531435A
(ja)
*
|
2006-03-24 |
2009-09-03 |
ワイス |
うつ病の治療用の新規な治療組み合わせ
|
|
WO2007112065A2
(en)
*
|
2006-03-24 |
2007-10-04 |
Wyeth |
Methods for treating cognitive and other disorders
|
|
WO2007112073A2
(en)
*
|
2006-03-24 |
2007-10-04 |
Wyeth |
Methods for modulating bladder function
|
|
EP1998781A2
(de)
*
|
2006-03-24 |
2008-12-10 |
Wyeth a Corporation of the State of Delaware |
Schmerzbehandlung
|
|
CA2644618A1
(en)
*
|
2006-03-24 |
2007-10-04 |
Wyeth |
Methods for treating cognitive and other disorders
|
|
US20070238789A1
(en)
*
|
2006-03-31 |
2007-10-11 |
Chin-Ming Chang |
Prednisolone acetate compositions
|
|
NZ572226A
(en)
*
|
2006-04-18 |
2011-05-27 |
Ekr Therapeutics Inc |
Pre-mixed, ready-to-use IV bolus compositions comprising nicardipine and methods of use
|
|
WO2007136640A2
(en)
*
|
2006-05-16 |
2007-11-29 |
Celgene Corporation |
Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione
|
|
CN100374468C
(zh)
*
|
2006-05-25 |
2008-03-12 |
重庆通量精细化工有限公司 |
水溶性磺烷基醚-β-环糊精的合成工艺
|
|
US8124773B2
(en)
|
2006-06-12 |
2012-02-28 |
Sunesis Pharmaceuticals, Inc. |
1,8-naphthyridine compounds for the treatment of cancer
|
|
JP2009539978A
(ja)
*
|
2006-06-13 |
2009-11-19 |
カーギル インコーポレイテッド |
大粒子シクロデキストリン包接複合体及びその製造方法
|
|
NZ597545A
(en)
|
2006-06-19 |
2013-07-26 |
Proteolix Inc |
Peptide epoxyketones for proteasome inhibition
|
|
US9428582B2
(en)
*
|
2006-07-03 |
2016-08-30 |
Genmab A/S |
Method of treating rash in patients undergoing anti-EGFR therapy
|
|
AR061889A1
(es)
|
2006-07-13 |
2008-10-01 |
Medichem Sa |
Proceso mejorado para la preparacion de voriconazol
|
|
US8323664B2
(en)
|
2006-07-25 |
2012-12-04 |
The Secretary Of State For Defence |
Live vaccine strains of Francisella
|
|
JP2009545601A
(ja)
|
2006-08-02 |
2009-12-24 |
サネシス ファーマシューティカルズ, インコーポレイテッド |
(+)−1,4−ジヒドロ−7−[(3s,4s)−3−メトキシ−4−(メチルアミノ)−1−ピロリジニル]−4−オキソ−1−(2−チアゾリル)−1,8−ナフチリジン−3−カルボン酸の組合せ使用
|
|
CL2007002218A1
(es)
*
|
2006-08-03 |
2008-03-14 |
Celgene Corp Soc Organizada Ba |
Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
|
|
CN101522623B
(zh)
|
2006-08-03 |
2013-06-12 |
塔夫茨大学信托人 |
无潮红烟酸类似物和其使用方法
|
|
EP2061459B1
(de)
|
2006-08-23 |
2012-12-26 |
Intellect Neurosciences Inc. |
3-(3-indolyl)propionsäure-calciumsalz und verfahren zur herstellung von 3-(3-indolyl)propionsäurefreier säure daraus
|
|
US8877780B2
(en)
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
|
CN100411688C
(zh)
*
|
2006-09-12 |
2008-08-20 |
南京师范大学 |
含有环糊精/多烯紫杉醇包合物的药物组合物及其制备方法
|
|
WO2008031221A1
(en)
|
2006-09-12 |
2008-03-20 |
Cephalin Pharmaceuticals Inc. |
Isovaline for treatment of pain
|
|
CN100486645C
(zh)
*
|
2006-09-12 |
2009-05-13 |
南京师范大学 |
含有环糊精紫杉醇包合物的药物组合物及其制备方法
|
|
US20100093861A1
(en)
|
2006-09-15 |
2010-04-15 |
Stevia Aps |
Treatment of insulin resistance or diseases associated with insulin resistance
|
|
US20090239942A1
(en)
*
|
2006-09-15 |
2009-09-24 |
Cloyd James C |
Topiramate Compositions and Methods of Making and Using the Same
|
|
PL2061458T3
(pl)
*
|
2006-09-15 |
2015-07-31 |
Univ Minnesota |
Kompozycje topiramatu i sposoby ich stosowania
|
|
JP5140080B2
(ja)
|
2006-09-21 |
2013-02-06 |
ラクオリア創薬株式会社 |
選択的アシッドポンプ阻害剤としてのベンゾイミダゾール誘導体
|
|
HUE035389T2
(en)
|
2006-09-26 |
2018-05-02 |
Celgene Corp |
5-substituted quinazolinone derivatives as anticancer agents
|
|
KR20090069330A
(ko)
|
2006-10-12 |
2009-06-30 |
와이어쓰 |
유백광/응집체를 감소시키기 위한 항체 용액 중의 이온 강도의 변화
|
|
GEP20125425B
(en)
|
2006-10-18 |
2012-03-26 |
Pfizer Prod Inc |
Biaryl ether urea compounds
|
|
ATE520651T1
(de)
|
2006-10-23 |
2011-09-15 |
Pfizer |
Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
|
|
MX2009004519A
(es)
|
2006-11-03 |
2009-05-12 |
Wyeth Corp |
Sustancias que inhiben la glucolisis en un cultivo de celulas.
|
|
WO2008063634A1
(en)
*
|
2006-11-21 |
2008-05-29 |
Novartis Ag |
Stable parenteral formulation containing a rsv inhibitor of a benzodiazepine structure
|
|
WO2008065142A1
(en)
*
|
2006-11-29 |
2008-06-05 |
N.V. Organon |
Stabilized solution of rocuronium comprising a sulfoalkyl-ether-beta-cyclodextrin derivative
|
|
WO2008067991A2
(en)
*
|
2006-12-08 |
2008-06-12 |
Antares Pharma Ipl Ag |
Skin-friendly drug complexes for transdermal administration
|
|
MX2009007084A
(es)
*
|
2006-12-27 |
2009-08-20 |
Cargill Inc |
Complejos de inclusion de ciclodextrina y metodos para preparar los mismos.
|
|
CA2679941C
(en)
|
2007-03-02 |
2016-09-20 |
Wyeth |
Use of copper and glutamate in cell culture for production of polypeptides
|
|
ES2373867T3
(es)
*
|
2007-03-02 |
2012-02-09 |
The University Of Wollongong |
Composiciones y procedimientos para el suministro de agentes anticancerosos.
|
|
WO2011084703A2
(en)
*
|
2009-12-21 |
2011-07-14 |
Advanced Liquid Logic, Inc. |
Enzyme assays on a droplet actuator
|
|
CN101686681B
(zh)
|
2007-04-27 |
2015-04-01 |
锡德克斯药物公司 |
包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法
|
|
US7960353B2
(en)
*
|
2007-05-10 |
2011-06-14 |
University Of Kansas |
Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
|
|
US20080283693A1
(en)
*
|
2007-05-15 |
2008-11-20 |
Evans Michael J F |
Propulsion apparatus and system
|
|
CA2689016C
(en)
|
2007-05-25 |
2014-08-12 |
Ipsen Pharma S.A.S. |
Melanocortin receptor ligands modified with hydantoin
|
|
ES2493641T3
(es)
*
|
2007-06-28 |
2014-09-12 |
Cydex Pharmaceuticals, Inc. |
Administración nasal de soluciones acuosas de corticosteroides
|
|
US12370352B2
(en)
|
2007-06-28 |
2025-07-29 |
Cydex Pharmaceuticals, Inc. |
Nasal and ophthalmic delivery of aqueous corticosteroid solutions
|
|
TWI428132B
(zh)
|
2007-07-02 |
2014-03-01 |
Lilly Co Eli |
癌症化療效果之強化
|
|
GB0714029D0
(en)
|
2007-07-18 |
2007-08-29 |
Novacta Biosystems Ltd |
Lantibiotic-based compounds having antimicrobial activity
|
|
GB0714030D0
(en)
|
2007-07-18 |
2007-08-29 |
Novacta Biosystems Ltd |
The use of type-B lantibiotic-based compounds having antimicrobial activity
|
|
WO2009018326A2
(en)
*
|
2007-07-31 |
2009-02-05 |
Limerick Biopharma, Inc. |
Soluble pyrone analogs methods and compositions
|
|
US7893045B2
(en)
|
2007-08-07 |
2011-02-22 |
Celgene Corporation |
Methods for treating lymphomas in certain patient populations and screening patients for said therapy
|
|
ES2452965T3
(es)
|
2007-09-05 |
2014-04-03 |
Rigel Pharmaceuticals, Inc. |
Sal de xinafoato de N4-[(2,2-difluoro-4H-benzo[1,4]oxazin-3-ona)-6-il]-5-fluoro-N2-[3-(metilaminocarbonilmetilenoxi)fenil]-2,4-pirimidindiamina
|
|
CL2008002777A1
(es)
*
|
2007-09-21 |
2010-01-22 |
Wyeth Corp |
Metodo de preparacion de compuestos diazepinoquinolinicos quirales por recristalizacion en un sistema de solvente ternario.
|
|
AU2008305581C1
(en)
|
2007-09-26 |
2014-12-11 |
Celgene Corporation |
6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising and methods of using the same
|
|
CA2701778C
(en)
|
2007-10-04 |
2018-09-11 |
Onyx Therapeutics, Inc. |
Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
|
|
US8518872B2
(en)
*
|
2007-10-22 |
2013-08-27 |
Sunesis Pharmaceuticals, Inc. |
Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-OXO-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid in combination therapy
|
|
US8192721B2
(en)
*
|
2007-12-13 |
2012-06-05 |
Verrow Pharmaceuticals, Inc. |
Compositions useful for reducing toxicity associated with gadolinium-based contrast agents
|
|
WO2009105256A2
(en)
*
|
2008-02-20 |
2009-08-27 |
Celgene Corporation |
Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand
|
|
WO2009107877A1
(en)
*
|
2008-02-28 |
2009-09-03 |
Takeda Pharmaceutical Company Limited |
Pharmaceutical composition
|
|
US8815953B2
(en)
*
|
2008-03-13 |
2014-08-26 |
Spectrum Pharmaceuticals, Inc. |
Formulations of vitamin K analogs for topical use
|
|
GB2458473A
(en)
|
2008-03-17 |
2009-09-23 |
Imuthes Ltd |
3'-O-allyl- and 3'-O-carboxymethyl- 2'-aminosaccharide derivatives, & amides thereof with peptides, as adjuvants
|
|
US7635773B2
(en)
|
2008-04-28 |
2009-12-22 |
Cydex Pharmaceuticals, Inc. |
Sulfoalkyl ether cyclodextrin compositions
|
|
AU2009241813A1
(en)
*
|
2008-04-30 |
2009-11-05 |
Neutron Row |
Methods of using corticotropin-releasing factor for the treatment of cancer
|
|
US20110224232A1
(en)
*
|
2008-05-06 |
2011-09-15 |
Board Of Regents, The University Of Texas System |
Treatment of Pulmonary Fungal Infection With Voriconazole via Inhalation
|
|
EP2303229A1
(de)
*
|
2008-06-16 |
2011-04-06 |
Debiopharm S.A. |
Konzentrierte oxaliplatin-lösung und herstellungsverfahren dafür
|
|
WO2010014617A1
(en)
*
|
2008-07-28 |
2010-02-04 |
University Of Kansas |
Heat shock protein 90 inhibitor dosing methods
|
|
JP5576370B2
(ja)
|
2008-08-06 |
2014-08-20 |
ファイザー・インク |
Chk−1阻害剤としての6置換2−ヘテロシクリルアミノピラジン化合物
|
|
CA2738328A1
(en)
|
2008-08-29 |
2010-03-04 |
Novogen Research Pty Ltd |
Immunomodulating activities
|
|
EP2163253B1
(de)
|
2008-09-15 |
2013-07-17 |
ULLRICH, Oliver |
Extrakte von der Pflanze Hornstedtia scyphifera und deren immunsuppressive Wirkungen
|
|
JP5675629B2
(ja)
|
2008-10-21 |
2015-02-25 |
オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. |
ペプチドエポキシケトンを用いた併用療法
|
|
CN102596196A
(zh)
*
|
2008-10-22 |
2012-07-18 |
诺沃根研究控股有限公司 |
用于诱导程序性细胞死亡的方法
|
|
EP3133160B1
(de)
|
2008-10-24 |
2018-12-12 |
Sarepta Therapeutics, Inc. |
Exon-skipping-zusammensetzungen für dmd
|
|
CA2957226C
(en)
|
2008-10-29 |
2018-08-14 |
Celgene Corporation |
Isoindoline compounds for use in the treatment of cancer
|
|
US10463677B2
(en)
|
2008-11-07 |
2019-11-05 |
Cydex Pharmaceuticals, Inc. |
Composition containing sulfoalkyl ether cyclodextrin and latanoprost
|
|
BR122020021551B1
(pt)
*
|
2008-11-15 |
2021-09-21 |
Melinta Subsidiary Corp |
Composição farmacêutica antimicrobiana e seu uso
|
|
RU2528406C2
(ru)
|
2008-11-21 |
2014-09-20 |
Раквалиа Фарма Инк. |
Новое производное пиразол-3-карбоксамида, обладающее антагонистической активностью в отношении рецептора 5-нт2в
|
|
AU2009330355B2
(en)
|
2008-12-16 |
2016-06-30 |
Sunovion Pharmaceuticals Inc. |
Triple reuptake inhibitors and methods of their use
|
|
JP2012512261A
(ja)
|
2008-12-17 |
2012-05-31 |
ジェネンテック, インコーポレイテッド |
C型肝炎ウイルス併用療法
|
|
EP2382214B1
(de)
|
2008-12-31 |
2017-07-19 |
Sunesis Pharmaceuticals, Inc. |
Verfahren zur herstellung von (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4- (methylamino)-1-pyrrolidinyl]-4-oxo-1-(2- thiazolyl)-1,8-naphthyridin-3- carbonsäure
|
|
CA2747419C
(en)
|
2009-01-12 |
2014-07-08 |
Icagen, Inc. |
Sulfonamide derivatives
|
|
WO2010082813A1
(en)
|
2009-01-13 |
2010-07-22 |
Academisch Medisch Centrum Bij De Universiteit Van Amsterdam |
Method of treating cancer
|
|
DK2387580T3
(da)
|
2009-01-14 |
2014-10-13 |
Novacta Biosystems Ltd |
Deoxyactagardinderivater
|
|
GB0900599D0
(en)
|
2009-01-14 |
2009-02-18 |
Novacta Biosystems Ltd |
Treatment
|
|
EA020733B1
(ru)
|
2009-02-04 |
2015-01-30 |
Новакта Биосистемс Лимитед |
Производные актагардина
|
|
MY160002A
(en)
|
2009-02-10 |
2017-02-15 |
Celgene Corp |
Methods of using and compositions comprising pde4 modulators for treatment, prevention and management of tuberculosis
|
|
EP2396312A1
(de)
|
2009-02-11 |
2011-12-21 |
Celgene Corporation |
Lenalidomidisotopologe
|
|
AU2010214101A1
(en)
|
2009-02-11 |
2011-09-01 |
Sunovion Pharmaceuticals Inc. |
Histamine H3 inverse agonists and antagonists and methods of use thereof
|
|
JP5936862B2
(ja)
|
2009-02-27 |
2016-06-22 |
サネシス ファーマシューティカルズ, インコーポレイテッド |
Brca2活性が低下した癌対象の治療のためのsns−595の使用方法
|
|
AU2010223268B2
(en)
|
2009-03-12 |
2015-04-23 |
Haase Investments Gmbh |
Bone morphogenetic protein 2 (BMP2 ) variants with reduced BMP antagonist sensitivity
|
|
AR075899A1
(es)
|
2009-03-20 |
2011-05-04 |
Onyx Therapeutics Inc |
Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
|
|
EP2233502A1
(de)
|
2009-03-27 |
2010-09-29 |
Deutsches Rheuma-Forschungszentrum Berlin |
Sialylierte antigenspezifische Antikörper zur Behandlung oder Vorbeugung von ungewollten entzündlichen Immunreaktionen und Verfahren zu deren Herstellung
|
|
WO2010116270A1
(en)
|
2009-04-10 |
2010-10-14 |
Pfizer Inc. |
Ep2/4 agonists
|
|
GB0906234D0
(en)
|
2009-04-14 |
2009-05-20 |
Secr Defence |
Vaccine
|
|
JP5699129B2
(ja)
|
2009-04-14 |
2015-04-08 |
イーライ リリー アンド カンパニー |
造血器新生物および白血病の治療のためのベンゾジアゼピン誘導体
|
|
PL3100728T3
(pl)
*
|
2009-05-13 |
2020-05-18 |
Cydex Pharmaceuticals, Inc. |
Kompozycje farmaceutyczne zawierające prasugrel i pochodne cyklodekstryny oraz sposoby ich wytwarzania i zastosowania
|
|
US20120134969A1
(en)
|
2009-05-25 |
2012-05-31 |
Hiroshi Handa |
Pharmaceutical composition containing nuclear factor involved in proliferation and differentiation of central neuronal cells
|
|
KR101522918B1
(ko)
*
|
2009-05-29 |
2015-05-27 |
사이덱스 파마슈티칼스, 인크. |
사이클로덱스트린 유도체를 포함하는 주사용 멜팔란 조성물 및 이의 제조 및 사용 방법
|
|
US11020363B2
(en)
|
2009-05-29 |
2021-06-01 |
Cydex Pharmaceuticals, Inc. |
Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
|
|
EP2435462A1
(de)
|
2009-05-29 |
2012-04-04 |
Pfizer Limited |
Neue glucocorticoidrezeptoragonisten
|
|
US8492538B1
(en)
|
2009-06-04 |
2013-07-23 |
Jose R. Matos |
Cyclodextrin derivative salts
|
|
KR20120035183A
(ko)
|
2009-06-10 |
2012-04-13 |
선오비온 파마슈티컬스 인코포레이티드 |
히스타민 h3 역 작용제 및 길항제, 및 이의 사용 방법
|
|
EP2266563A1
(de)
|
2009-06-11 |
2010-12-29 |
Charité-Universitätsmedizin Berlin (Charité) |
Verwendung von Opiodrezeptorantagonisten zur akuten Behandlung von paraphilischen Erregungszuständen
|
|
SMT202000093T1
(it)
|
2009-06-16 |
2020-03-13 |
Pfizer |
Forme di dosaggio di apixaban
|
|
KR20120124353A
(ko)
|
2009-06-24 |
2012-11-13 |
스티븐 에반스-프레케 |
암 치료를 위해 코르티코트로핀 방출인자를 사용하는 방법
|
|
WO2011004276A1
(en)
|
2009-07-06 |
2011-01-13 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
|
DE102009034368A1
(de)
|
2009-07-20 |
2011-01-27 |
Bayer Schering Pharma Aktiengesellschaft |
17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
|
|
EA201270283A1
(ru)
|
2009-08-19 |
2012-12-28 |
Рациофарм Гмбх |
Способ получения соэвапоратов и комплексы, содержащие вориконазол и циклодекстрин
|
|
JP2013504580A
(ja)
|
2009-09-11 |
2013-02-07 |
スノヴィオン ファーマシューティカルズ インコーポレイテッド |
ヒスタミンh3インバースアゴニストおよびアンタゴニストとその使用方法
|
|
US20110082098A1
(en)
*
|
2009-09-30 |
2011-04-07 |
University Of Kansas |
Novobiocin analogues and treatment of polycystic kidney disease
|
|
WO2011060179A1
(en)
|
2009-11-13 |
2011-05-19 |
Onyx Therapeutics, Inc |
Use of peptide epoxyketones for metastasis suppression
|
|
AU2010319314C1
(en)
|
2009-11-13 |
2016-09-01 |
Sarepta Therapeutics, Inc. |
Antisense antiviral compound and method for treating influenza viral infection
|
|
MX2012004741A
(es)
|
2009-11-19 |
2012-05-22 |
Celgene Corp |
Apremilast para el tratamiento de sarcoidosis.
|
|
WO2011064558A2
(en)
|
2009-11-30 |
2011-06-03 |
Cipla Limited |
Pharmaceutical composition
|
|
CN104193761B
(zh)
|
2009-12-04 |
2017-10-17 |
桑诺维恩药品公司 |
多环化合物及其使用方法
|
|
CA2784830C
(en)
|
2009-12-18 |
2018-03-27 |
Sunovion Pharmaceuticals Inc. |
Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof
|
|
AU2010333767A1
(en)
|
2009-12-22 |
2012-07-05 |
Celgene Corporation |
(Methylsulfonyl) ethyl benzene isoindoline derivatives and their therapeutical uses
|
|
WO2011077313A1
(en)
|
2009-12-22 |
2011-06-30 |
Pfizer Inc. |
Piperidinecarboxamides as mpges - 1 inhibitors
|
|
EP2516434B1
(de)
|
2009-12-23 |
2015-05-27 |
Takeda Pharmaceutical Company Limited |
Geschmolzene heteroaromatische pyrrolidinone als syk-hemmer
|
|
MX337566B
(es)
|
2010-01-05 |
2016-03-10 |
Celgene Corp |
Combinación de un compuesto inmunomodulador y una artemisinina o un derivado de ésta para tratar cáncer.
|
|
WO2011083387A1
(en)
|
2010-01-07 |
2011-07-14 |
Pfizer Limited |
Hydrochloride salt of biphenyl-2-yl-carbamic acid 1-{9-[(3-fluoro-4-hydroxy-benzoyl)-methyl-amino]-nonyl}-piperidin-4-yl ester
|
|
GB201001688D0
(en)
|
2010-02-02 |
2010-03-17 |
Novacta Biosystems Ltd |
Compounds
|
|
MX2012008819A
(es)
|
2010-02-02 |
2012-09-28 |
Novacta Biosystems Ltd |
Sales de lantibioticos.
|
|
SG183257A1
(en)
|
2010-02-11 |
2012-09-27 |
Celgene Corp |
Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
|
|
WO2011104649A1
(en)
|
2010-02-25 |
2011-09-01 |
Pfizer Limited |
Peptide analogues
|
|
AU2011223795B2
(en)
|
2010-03-01 |
2015-11-05 |
Onyx Therapeutics, Inc. |
Compounds for immunoproteasome inhibition
|
|
TWI509247B
(zh)
*
|
2010-03-12 |
2015-11-21 |
西建公司 |
利用雷那度胺(lenalidomide)治療非霍奇金氏淋巴瘤之方法及作為預測子之基因及蛋白質生物標記
|
|
US9068185B2
(en)
|
2010-03-12 |
2015-06-30 |
Sarepta Therapeutics, Inc. |
Antisense modulation of nuclear hormone receptors
|
|
CA2795559A1
(en)
|
2010-04-07 |
2011-11-03 |
Onyx Therapeutics, Inc. |
Crystalline peptide epoxyketone immunoproteasome inhibitor
|
|
CA2796967C
(en)
|
2010-05-04 |
2015-12-01 |
Pfizer Inc. |
Heterocyclic derivatives as alk inhibitors
|
|
EP3023496B1
(de)
|
2010-05-13 |
2020-07-29 |
Sarepta Therapeutics, Inc. |
Verbindungen, die die signalaktivität von interleukin-17- und interleukin-23 modulieren
|
|
MX338405B
(es)
|
2010-05-26 |
2016-04-14 |
Neurophyxia B V |
Formulaciones de 2-iminobiotina y sus usos.
|
|
WO2011150156A2
(en)
|
2010-05-26 |
2011-12-01 |
Sunovion Pharmaceuticals Inc. |
Heteroaryl compounds and methods of use thereof
|
|
WO2011154871A1
(en)
|
2010-06-10 |
2011-12-15 |
Pfizer Limited |
Hepatitis c virus inhibitors
|
|
CA2802952A1
(en)
|
2010-06-24 |
2011-12-29 |
Arisaph Pharmaceuticals, Inc. |
Niacin mimetics, and methods of use thereof
|
|
AU2011270719B2
(en)
|
2010-06-24 |
2015-09-24 |
Arisaph Pharmaceuticals, Inc. |
Niacin mimetics, and methods of use thereof
|
|
PL3391890T3
(pl)
|
2010-06-29 |
2021-12-20 |
Merck Sharp & Dohme Corp. |
Preparaty dożylnego roztworu pozakonazolu stabilizowane podstawioną beta-cyklodekstryną
|
|
NL2005052C2
(en)
|
2010-07-07 |
2012-01-10 |
Caroline Haaften |
Xanthanodien for the treatment of cancer.
|
|
WO2012004743A1
(en)
|
2010-07-09 |
2012-01-12 |
Pfizer Limited |
Benzenesulfonamides useful as sodium channel inhibitors
|
|
ES2526675T3
(es)
|
2010-07-09 |
2015-01-14 |
Pfizer Limited |
N-sulfonilbenzamidas como inhibidores de los canales de sodio dependientes de voltaje
|
|
JP5872552B2
(ja)
|
2010-07-09 |
2016-03-01 |
ファイザー・リミテッドPfizer Limited |
化学化合物
|
|
CA2804351A1
(en)
|
2010-07-12 |
2012-01-19 |
Pfizer Limited |
Chemical compounds
|
|
EP2593431B1
(de)
|
2010-07-12 |
2014-11-19 |
Pfizer Limited |
N-sulfonylbenzamide als inhibitoren von spannungsabhängigen natriumkanälen
|
|
EP2593427B1
(de)
|
2010-07-12 |
2014-12-24 |
Pfizer Limited |
Sulfonamidderivate als nav1.7-inhibitoren zur schmerzbehandlung
|
|
JP2013532184A
(ja)
|
2010-07-12 |
2013-08-15 |
ファイザー・リミテッド |
電位開口型ナトリウムチャネル阻害剤として有用なn−スルホニルベンズアミド誘導体
|
|
EP2593428B1
(de)
|
2010-07-12 |
2014-11-19 |
Pfizer Limited |
N-sulfonylbenzamide als inhibitoren von spannungsabhängigen natriumkanälen
|
|
EP2409699B1
(de)
|
2010-07-23 |
2014-04-30 |
Combino Pharm, S.L. |
Stabile Voriconazole-enthaltende Zusammensetzungen
|
|
GB201013509D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Compounds
|
|
GB201013508D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Compounds
|
|
GB201013507D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Compounds
|
|
GB201013513D0
(en)
|
2010-08-11 |
2010-09-22 |
Novacta Biosystems Ltd |
Formulations
|
|
WO2012025217A1
(en)
|
2010-08-24 |
2012-03-01 |
Algiax Pharmaceuticals Gmbh |
Novel use of leflunomide and malononitrilamides
|
|
CN103180333A
(zh)
|
2010-08-24 |
2013-06-26 |
英皇创新有限公司 |
聚丙基醚亚胺的糖树状聚体
|
|
WO2012042421A1
(en)
|
2010-09-29 |
2012-04-05 |
Pfizer Inc. |
Method of treating abnormal cell growth
|
|
HUE034890T2
(hu)
|
2010-10-29 |
2018-03-28 |
Algiax Pharmaceuticals Gmbh |
Malononitrilaminok alkalmazása neuropathiás fájdalomban
|
|
WO2012061409A1
(en)
|
2010-11-01 |
2012-05-10 |
Marshall Edwards, Inc. |
Isoflavonoid compounds and methods for the treatment of cancer
|
|
CA2817896A1
(en)
|
2010-11-15 |
2012-05-24 |
Viiv Healthcare Uk Limited |
Inhibitors of hiv replication
|
|
WO2012078492A1
(en)
|
2010-12-06 |
2012-06-14 |
Celgene Corporation |
A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
|
|
ES2673114T3
(es)
|
2011-01-10 |
2018-06-19 |
Celgene Corporation |
Derivados de fenetilsulfona isoindolina como inhibidores de PDE 4 y/o citoquinas
|
|
JP6106603B2
(ja)
|
2011-01-11 |
2017-04-05 |
スノビオン プハルマセウトイカルス インコーポレイテッド |
ヘテロアリール化合物及びその使用方法
|
|
WO2012095781A1
(en)
|
2011-01-13 |
2012-07-19 |
Pfizer Limited |
Indazole derivatives as sodium channel inhibitors
|
|
WO2012097116A2
(en)
|
2011-01-14 |
2012-07-19 |
Celgene Corporation |
Isotopologues of isoindole derivatives
|
|
WO2012100142A2
(en)
|
2011-01-20 |
2012-07-26 |
Cornell University |
Treatments for retinal disorders
|
|
AU2012209184B2
(en)
|
2011-01-26 |
2017-06-15 |
Allergan, Inc. |
Androgen composition for treating an opthalmic condition
|
|
JP2014503597A
(ja)
|
2011-01-31 |
2014-02-13 |
セルジーン コーポレイション |
シチジンアナログの医薬組成物及びその使用方法
|
|
JP5931933B2
(ja)
|
2011-02-25 |
2016-06-08 |
武田薬品工業株式会社 |
N−置換オキサジノプテリジンおよびオキサジノプテリジノン
|
|
WO2012120398A1
(en)
|
2011-03-04 |
2012-09-13 |
Pfizer Limited |
Aryl substituted carboxamide derivatives as trpm8 modulators
|
|
WO2012120365A1
(en)
|
2011-03-07 |
2012-09-13 |
Aurobindo Pharma Limited |
Stable pharmaceutical composition comprising ethinyl estradiol
|
|
RU2611007C2
(ru)
|
2011-03-11 |
2017-02-17 |
Селджин Корпорейшн |
Твердые формы 3-(5-амино-2-метил-4-оксо-4н-хиназолин-3-ил)пиперидин-2, 6-диона и их фармацевтические композиции и применение
|
|
SI2683384T1
(sl)
|
2011-03-11 |
2016-05-31 |
Celgene Corporation |
Metode zdravljenja raka z uporabo 3-(5-amino-2-metil-4-okso-4H-kinazolin-3-il)-piperidin-2,6-diona
|
|
EP2685975A1
(de)
|
2011-03-17 |
2014-01-22 |
Algiax Pharmaceuticals GmbH |
Neue verwendung von benzofuranylsulfonaten
|
|
WO2012123406A1
(en)
|
2011-03-17 |
2012-09-20 |
Algiax Pharmaceuticals Gmbh |
Novel use of imidazotriazinones
|
|
EP2699091B1
(de)
|
2011-03-28 |
2017-06-21 |
DeuteRx, LLC |
2',6'-dioxo-3'-deutero-piperidin-3-yl-isoindolin-verbindungen
|
|
RU2464042C1
(ru)
*
|
2011-03-31 |
2012-10-20 |
Общество С Ограниченной Ответственностью "Научно-Исследовательская Компания "Медбиофарм" |
КЛАТРАТНЫЙ КОМПЛЕКС β-ЦИКЛОДЕКСТРИНА С ПРОИЗВОДНЫМ 5-ГИДРОКСИ-4-АМИНОМЕТИЛ-1-ЦИКЛОГЕКСИЛ(ИЛИ ЦИКЛОГЕПТИЛ)-3-АЛКОКСИКАРБОНИЛИНДОЛА, СПОСОБ ЕГО ПОЛУЧЕНИЯ (ВАРИАНТЫ), ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ЛЕКАРСТВЕННОЕ СРЕДСТВО
|
|
EP2694509B1
(de)
|
2011-04-05 |
2016-05-18 |
Pfizer Limited |
Pyrrolo[2,3-d]pyrimidinderivate als inhibitoren von tropomyosin-verwandten kinasen
|
|
WO2012138214A1
(en)
|
2011-04-08 |
2012-10-11 |
Brewster Lizzy Maritza |
Beta-guanidinopropionic acid for the treatment of hypertension
|
|
WO2012149299A2
(en)
|
2011-04-29 |
2012-11-01 |
Celgene Corporaiton |
Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor
|
|
CN103702995B
(zh)
|
2011-05-18 |
2016-04-13 |
拉夸里亚创药株式会社 |
4-{[4-({[4-(2,2,2-三氟乙氧基)-1,2-苯并异噁唑-3-基]氧}甲基)哌啶-1-基]甲基}-四氢-2h-吡喃-4-羧酸的多晶型形式
|
|
TWI544922B
(zh)
|
2011-05-19 |
2016-08-11 |
愛爾康研究有限公司 |
高濃度歐羅派特錠(olopatadine)眼用組成物
|
|
WO2012163546A1
(en)
*
|
2011-06-03 |
2012-12-06 |
Ratiopharm Gmbh |
Pharmaceutical composition comprising dapagliflozin and cyclodextrin
|
|
PL2720723T3
(pl)
|
2011-06-15 |
2018-10-31 |
Synthon Bv |
Stabilizowana kompozycja worykonazolu
|
|
WO2012177678A2
(en)
|
2011-06-22 |
2012-12-27 |
Celgene Corporation |
Isotopologues of pomalidomide
|
|
WO2012177714A1
(en)
|
2011-06-22 |
2012-12-27 |
Takeda Pharmaceutical Company Limited |
Substituted 6-aza-isoindolin-1-one derivatives
|
|
WO2013009927A2
(en)
|
2011-07-11 |
2013-01-17 |
Advanced Liquid Logic, Inc. |
Droplet actuators and techniques for droplet-based assays
|
|
WO2013008123A1
(en)
|
2011-07-13 |
2013-01-17 |
Pfizer Limited |
Enkephalin analogues
|
|
CA2839593A1
(en)
|
2011-07-15 |
2013-01-24 |
Sarepta Therapeutics, Inc. |
Methods and compositions for manipulating translation of protein isoforms from alternative initiation start sites
|
|
US8575336B2
(en)
|
2011-07-27 |
2013-11-05 |
Pfizer Limited |
Indazoles
|
|
US20160206608A1
(en)
|
2011-08-02 |
2016-07-21 |
Pfizer Inc. |
Crizotinib for use in the treatment of cancer
|
|
EP2739274A1
(de)
|
2011-08-02 |
2014-06-11 |
Pensieve Biosciences Cyprus Limited |
Behandlung von kognitiver störung
|
|
EP2561863A1
(de)
|
2011-08-22 |
2013-02-27 |
Farmaprojects, S.A.U. |
Pharmazeutische Zusammensetzungen mit Voriconazol
|
|
EP2758052B9
(de)
|
2011-09-18 |
2019-03-27 |
Euro-Celtique S.A. |
HDAC-Hemmer-Cyclopolysaccharidzusammensetzung
|
|
US10478505B2
(en)
|
2011-09-23 |
2019-11-19 |
The Regents Of The University Of California |
Edible oils to enhance delivery of orally administered steroids
|
|
WO2013054185A1
(en)
|
2011-10-13 |
2013-04-18 |
Pfizer, Inc. |
Pyrimidine and pyridine derivatives useful in therapy
|
|
JP5363636B2
(ja)
|
2011-10-21 |
2013-12-11 |
ファイザー・リミテッド |
新規な塩および医学的使用
|
|
BR112014009102A2
(pt)
|
2011-10-26 |
2017-04-18 |
Pfizer Ltd |
compostos químicos
|
|
EP3243815B1
(de)
|
2011-10-28 |
2019-07-10 |
Inhibitaxin Limited |
Pyridazinderivate für therapeutische zwecke
|
|
WO2013086444A2
(en)
|
2011-12-08 |
2013-06-13 |
Sarepta Therapeutics, Inc. |
Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human lmna
|
|
ES2593533T3
(es)
|
2011-12-15 |
2016-12-09 |
Pfizer Limited |
Derivados de sulfonamida
|
|
WO2013093688A1
(en)
|
2011-12-19 |
2013-06-27 |
Pfizer Limited |
Sulfonamide derivatives and use thereof as vgsc inhibitors
|
|
EA201491265A1
(ru)
|
2011-12-23 |
2014-11-28 |
Новартис Аг |
Соединения для ингибирования взаимодействия bcl-2 с партнерами по связыванию
|
|
AU2012355613A1
(en)
|
2011-12-23 |
2014-07-17 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
|
AU2012355624A1
(en)
|
2011-12-23 |
2014-07-17 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
|
AU2012355623A1
(en)
|
2011-12-23 |
2014-07-17 |
Novartis Ag |
Compounds for inhibiting the interaction of BCL2 with binding partners
|
|
CA2859873A1
(en)
|
2011-12-23 |
2013-06-27 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
|
TW201332572A
(zh)
|
2011-12-28 |
2013-08-16 |
Otsuka Pharma Co Ltd |
具有經取代的β-環糊精之藥物製劑
|
|
CA2860553C
(en)
|
2012-01-04 |
2016-08-23 |
Pfizer Limited |
N-aminosulfonyl benzamides
|
|
SG10201606063RA
(en)
|
2012-01-23 |
2016-09-29 |
Sage Therapeutics Inc |
Neuroactive steroid formulations and methods of treating cns disorders
|
|
GB201201332D0
(en)
|
2012-01-26 |
2012-03-14 |
Imp Innovations Ltd |
Method
|
|
TWI573792B
(zh)
|
2012-02-01 |
2017-03-11 |
歐陸斯迪公司 |
新穎治療劑
|
|
WO2013114250A1
(en)
|
2012-02-03 |
2013-08-08 |
Pfizer Inc. |
Benziimidazole and imidazopyridine derivatives as sodium channel modulators
|
|
AU2013216935C1
(en)
|
2012-02-08 |
2017-12-14 |
John Emmerson Campbell |
Heteroaryl compounds and methods of use thereof
|
|
TW201336527A
(zh)
|
2012-02-10 |
2013-09-16 |
Alcon Res Ltd |
具增強的穩定性之水性藥學組成物
|
|
HUE058834T2
(hu)
|
2012-02-15 |
2022-09-28 |
Cydex Pharmaceuticals Inc |
Elõállítási eljárás ciklodextrin-származékokhoz
|
|
US9085551B2
(en)
|
2012-02-21 |
2015-07-21 |
Celgene Corporation |
Solid forms of 3-(4-nitro-1-oxisoindolin-2-yl)piperidine-2,6-dione
|
|
MX353603B
(es)
|
2012-02-28 |
2018-01-19 |
Cydex Pharmaceuticals Inc |
Composiciones de ciclodextrina alquilada y procesos para preparar y utilizar las mismas.
|
|
WO2013129929A1
(en)
|
2012-03-02 |
2013-09-06 |
Erasmus University Medical Center Rotterdam |
Methods for activating retrovirus in latent infected cells, and compounds for use therein
|
|
CA2863892C
(en)
|
2012-03-06 |
2016-08-30 |
Pfizer Inc. |
Macrocyclic derivatives for the treatment of proliferative diseases
|
|
WO2013148603A1
(en)
|
2012-03-27 |
2013-10-03 |
Takeda Pharmaceutical Company Limited |
Cinnoline derivatives as as btk inhibitors
|
|
EP2854553B1
(de)
|
2012-03-30 |
2016-12-21 |
SapioTec GmbH |
Verwendung von delphinidin gegen staphylococcus aureus
|
|
US20150087822A1
(en)
|
2012-03-30 |
2015-03-26 |
Sapiotec Gmbh |
Anthocyanidin complex
|
|
WO2013156232A1
(en)
|
2012-04-16 |
2013-10-24 |
Algiax Pharmaceuticals Gmbh |
Use of benzofuranylsulfonates in neuropathic pain
|
|
WO2013156231A1
(en)
|
2012-04-16 |
2013-10-24 |
Algiax Pharmaceuticals Gmbh |
Use of imidazotriazinones in neuropathic pain
|
|
BR112014028069A2
(pt)
|
2012-05-11 |
2017-08-08 |
Cipla Ltd |
composição farmacêutica oftálmica, processo para a preparação de uma composição farmacêutica oftálmica, uso de uma composição farmacêutica oftálmica, e, método para a prevenção ou tratamento de uma infecção fúngica
|
|
ES2670601T3
(es)
|
2012-05-15 |
2018-05-31 |
Novartis Ag |
Derivados de benzamida para la inhibición de la actividad de ABL1, ABL2 y BCR-ABL1
|
|
KR20150008406A
(ko)
|
2012-05-15 |
2015-01-22 |
노파르티스 아게 |
Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 벤즈아미드 유도체
|
|
MX357305B
(es)
|
2012-05-15 |
2018-07-04 |
Novartis Ag |
Compuestos y composiciones para inhibir la actividad de abl-1, abl-2, y bcr-abl1.
|
|
WO2013171640A1
(en)
|
2012-05-15 |
2013-11-21 |
Novartis Ag |
Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
|
|
WO2013183985A1
(en)
|
2012-06-05 |
2013-12-12 |
Erasmus University Medical Center Rotterdam |
Method of treating cognitive impairment and compounds for use therein
|
|
ES2872967T3
(es)
|
2012-06-29 |
2021-11-03 |
Celgene Corp |
Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS)
|
|
WO2014011695A2
(en)
|
2012-07-09 |
2014-01-16 |
Onyx Therapeutics, Inc. |
Prodrugs of peptide epoxy ketone protease inhibitors
|
|
UY34893A
(es)
|
2012-07-10 |
2014-02-28 |
Takeda Pharmaceutical |
Derivados de azaindol
|
|
WO2014015027A1
(en)
|
2012-07-18 |
2014-01-23 |
Onyx Therapeutics, Inc. |
Liposomal compositions of epoxyketone-based proteasome inhibitors
|
|
KR20210073616A
(ko)
|
2012-08-09 |
2021-06-18 |
셀진 코포레이션 |
면역-관련 및 염증성 질환의 치료
|
|
LT2882737T
(lt)
|
2012-08-09 |
2019-04-25 |
Celgene Corporation |
(s)-3-(4-((4-morfolinometil)benzil)oksi)-1-oksoizoindolin-2-il)piperidin-2,6-diono hidrochlorido kieta forma
|
|
UA116544C2
(uk)
|
2012-08-09 |
2018-04-10 |
Селджин Корпорейшн |
Спосіб лікування раку з використанням 3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
|
|
US9587281B2
(en)
|
2012-08-14 |
2017-03-07 |
Celgene Corporation |
Cereblon isoforms and their use as biomarkers for therapeutic treatment
|
|
RS62761B1
(sr)
|
2012-08-21 |
2022-01-31 |
Sage Therapeutics Inc |
Alopregnanolon za lečenje refraktornog epileptičkog statusa
|
|
CA2883130A1
(en)
|
2012-08-31 |
2014-03-06 |
The General Hospital Corporation |
Biotin complexes for treatment and diagnosis of alzheimer's disease
|
|
US9475816B2
(en)
|
2012-09-07 |
2016-10-25 |
Takeda Pharmaceutical Company Limited |
Substituted-1,4-dihydropyrazolo[4,3-b]indoles
|
|
CN104797256A
(zh)
|
2012-09-10 |
2015-07-22 |
细胞基因公司 |
用于治疗局部晚期乳腺癌的方法
|
|
US9533989B2
(en)
|
2012-09-18 |
2017-01-03 |
Ziarco Pharma Ltd. |
Substituted pyrimidine-5-carboxamides as spleen tyrosine kinase inhibitors
|
|
JP6254169B2
(ja)
|
2012-09-28 |
2017-12-27 |
ファイザー・インク |
ベンズアミドおよびヘテロベンズアミド化合物
|
|
CA2885259A1
(en)
|
2012-10-04 |
2014-04-10 |
Pfizer Limited |
Pyrrolo[3,2-c]pyridine tropomyosin-related kinase inhibitors
|
|
CA2885247A1
(en)
|
2012-10-04 |
2014-04-10 |
Pfizer Limited |
Tropomyosin-related kinase inhibitors
|
|
JP2015531394A
(ja)
|
2012-10-04 |
2015-11-02 |
ファイザー・リミテッドPfizer Limited |
ピロロ[2,3−d]ピリミジントロポミオシン関連キナーゼ阻害剤
|
|
WO2014066274A1
(en)
|
2012-10-22 |
2014-05-01 |
Cydex Pharmaceuticals, Inc. |
Alkylated cyclodextrin compositions and processes for preparing and using the same
|
|
WO2014072881A1
(en)
|
2012-11-08 |
2014-05-15 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
|
CA2889572C
(en)
|
2012-11-08 |
2019-03-05 |
Pfizer Inc. |
Heteroaromatic compounds as dopamine d1 ligands
|
|
EP2916869A1
(de)
|
2012-11-09 |
2015-09-16 |
Celgene Corporation |
Verfahren zur behandlung von knochenschwund
|
|
US9925274B2
(en)
|
2012-11-15 |
2018-03-27 |
Sapiotec Gmbh |
Delphinidin complex as an antiphlogistic or immunosuppressive active ingredient
|
|
TWI610929B
(zh)
|
2012-11-21 |
2018-01-11 |
拉夸里亞創藥股份有限公司 |
多形體形式
|
|
US9670230B2
(en)
|
2012-11-29 |
2017-06-06 |
Sunovion Pharmaceuticals Inc. |
Heteroaryl compounds and methods of use thereof
|
|
US20150313915A1
(en)
|
2012-11-30 |
2015-11-05 |
The Regents Of The University Of California |
Anticonvulsant activity of steroids
|
|
MY176727A
(en)
|
2012-12-03 |
2020-08-20 |
Pfizer |
Selective androgen receptor modulators
|
|
JP6234475B2
(ja)
|
2012-12-11 |
2017-11-22 |
ザピオテック・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングSAPIOTEC GmbH |
メラノーマ細胞に対抗するためのデルフィニジン
|
|
UA112028C2
(uk)
|
2012-12-14 |
2016-07-11 |
Пфайзер Лімітед |
Похідні імідазопіридазину як модулятори гамка-рецептора
|
|
CN106414739A
(zh)
|
2012-12-20 |
2017-02-15 |
萨雷普塔医疗公司 |
用于治疗肌营养不良症的改良的外显子跳跃组合物
|
|
UA111305C2
(uk)
|
2012-12-21 |
2016-04-11 |
Пфайзер Інк. |
Конденсовані лактами арилу та гетероарилу
|
|
WO2014106238A1
(en)
|
2012-12-31 |
2014-07-03 |
Fang, Qun, Kevin |
Heterocyclic compounds and methods of use thereof
|
|
AU2014205043B2
(en)
|
2013-01-14 |
2018-10-04 |
Deuterx, Llc |
3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
|
|
US9695145B2
(en)
|
2013-01-22 |
2017-07-04 |
Celgene Corporation |
Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
|
|
NZ710385A
(en)
|
2013-02-19 |
2016-10-28 |
Novartis Ag |
Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
|
|
DK3431475T3
(da)
|
2013-02-21 |
2021-05-25 |
Pfizer |
Faste former af en selektiv CDK4/6-hæmmer
|
|
JO3377B1
(ar)
|
2013-03-11 |
2019-03-13 |
Takeda Pharmaceuticals Co |
مشتقات بيريدينيل وبيريدينيل مندمج
|
|
US9217148B2
(en)
|
2013-03-14 |
2015-12-22 |
Sarepta Therapeutics, Inc. |
Exon skipping compositions for treating muscular dystrophy
|
|
CN105188759A
(zh)
*
|
2013-03-14 |
2015-12-23 |
阿勒根公司 |
持续释放递送的组合物以及在制造过程中稳定蛋白质的方法
|
|
EP3760720A1
(de)
|
2013-03-14 |
2021-01-06 |
Sarepta Therapeutics, Inc. |
Verbesserte exon-skipping-zusammensetzungen zur behandlung von muskeldystrophie
|
|
HK1220154A1
(zh)
|
2013-03-15 |
2017-04-28 |
Sarepta Therapeutics, Inc. |
改进的用於治疗肌营养不良的组合物
|
|
EP2784083A1
(de)
|
2013-03-28 |
2014-10-01 |
Charité - Universitätsmedizin Berlin |
Knochenmorphogenetische Protein (BMP)-Varianten mit hoch reduzierter Antagonisten-Sensibilität und erweiterter spezifischer biologischer Aktivität
|
|
EP2981262A1
(de)
|
2013-04-02 |
2016-02-10 |
Celgene Corporation |
Verfahren und zusammensetzungen mit 4-amino-2-(2,6-dioxo-piperidin-3-yl)-isoindolin-1,3-dion zur behandlung von krebserkrankungen des zentralnervensystems
|
|
EP2792360A1
(de)
|
2013-04-18 |
2014-10-22 |
IP Gesellschaft für Management mbH |
(1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide zur Verwendung bei der Behandlung von HCV
|
|
TW201443025A
(zh)
|
2013-04-19 |
2014-11-16 |
Pfizer Ltd |
化學化合物
|
|
TW201512171A
(zh)
|
2013-04-19 |
2015-04-01 |
Pfizer Ltd |
化學化合物
|
|
WO2014181213A1
(en)
|
2013-05-10 |
2014-11-13 |
Pfizer Inc. |
Crystalline form of (sa)-(-)-3-(3-bromo-4-((2,4-difluorobenzyl)oxy)-6-methyl-2-oxopyridin-1 (2h)-yl)-n,4-dimethylbenzamide
|
|
EP2815749A1
(de)
|
2013-06-20 |
2014-12-24 |
IP Gesellschaft für Management mbH |
Feste Form von 4-Amino-2-(2,6-dioxopiperidin-3-yl)isoindolin-1,3-dion mit spezifischem Röntgenbeugungsspektrum
|
|
PE20160664A1
(es)
|
2013-06-27 |
2016-07-09 |
Pfizer |
Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina
|
|
PE20160221A1
(es)
|
2013-07-08 |
2016-05-22 |
Abbvie Inc |
Formas de dosificacion farmaceuticas estabilizadas que comprenden atrasentan
|
|
GB201312737D0
(en)
|
2013-07-17 |
2013-08-28 |
Univ Greenwich |
Cyclodextrin
|
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
|
US8962675B1
(en)
|
2013-09-12 |
2015-02-24 |
Abbvie Inc. |
Atrasentan mandelate salts
|
|
CN104513253A
(zh)
|
2013-10-01 |
2015-04-15 |
南京波尔泰药业科技有限公司 |
用于治疗增殖性疾病的大环化合物
|
|
WO2015092634A1
(en)
|
2013-12-16 |
2015-06-25 |
Novartis Ag |
1,2,3,4-tetrahydroisoquinoline compounds and compositions as selective estrogen receptor antagonists and degraders
|
|
JP2016540811A
(ja)
|
2013-12-20 |
2016-12-28 |
ファイザー・リミテッドPfizer Limited |
N−アシルピペリジンエーテルトロポミオシン関連キナーゼ阻害剤
|
|
WO2015106014A1
(en)
|
2014-01-09 |
2015-07-16 |
Takeda Pharmaceutical Company Limited |
Azaindole derivatives
|
|
US9371321B2
(en)
|
2014-01-09 |
2016-06-21 |
Astrazeneca Ab |
Azaindole derivatives
|
|
CN103694376B
(zh)
|
2014-01-10 |
2016-04-13 |
凯莱英医药集团(天津)股份有限公司 |
一种制备磺丁基醚-β-环糊精的方法
|
|
ES2831326T3
(es)
|
2014-01-15 |
2021-06-08 |
Poxel Sa |
Métodos para tratar trastornos neurológicos, metabólicos y otros mediante el uso de pioglitazona enantiopura enriquecida con deuterio
|
|
ES2699351T3
(es)
|
2014-01-17 |
2019-02-08 |
Novartis Ag |
Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2
|
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
|
WO2015107494A1
(en)
|
2014-01-17 |
2015-07-23 |
Novartis Ag |
1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2
|
|
EP2913050A1
(de)
|
2014-02-28 |
2015-09-02 |
SapioTec GmbH |
Verfahren zur Herstellung eines Flurankomplexes
|
|
WO2015140081A1
(en)
|
2014-03-18 |
2015-09-24 |
Algiax Pharmaceuticals Gmbh |
2-cyano-3-cyclopropyl-3-hydroxy-n-aryl-thioacrylamide derivatives
|
|
US20170197939A1
(en)
|
2014-04-15 |
2017-07-13 |
Pfizer Inc. |
Tropomyosin-Related Kinase Inhibitors Containing Both A 1H-Pyrazole And A Pyrimidine Moiety
|
|
SG11201607990QA
(en)
|
2014-04-25 |
2016-11-29 |
Pfizer |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
|
JP6239149B2
(ja)
|
2014-04-25 |
2017-11-29 |
ファイザー・インク |
複素芳香族化合物およびそのドーパミンd1リガンドとしての使用
|
|
WO2015162518A1
(en)
|
2014-04-25 |
2015-10-29 |
Pfizer Inc. |
Heteroaromatic compounds and their use as dopamine d1 ligands
|
|
EP3137454A1
(de)
|
2014-04-28 |
2017-03-08 |
Pfizer Inc. |
Heteroaromatische verbindungen und deren verwendung als dopamin-d1-liganden
|
|
CA2946990A1
(en)
|
2014-04-28 |
2015-11-05 |
Pfizer Inc. |
Heterocyclic compounds and their use as dopamine d1 ligands
|
|
US20170065589A1
(en)
|
2014-05-06 |
2017-03-09 |
Anthony G. Visco |
Methods of treating or preventing preterm labor
|
|
EP3140298A1
(de)
|
2014-05-07 |
2017-03-15 |
Pfizer Inc. |
Tropomyosin-assoziierte kinaseinhibitoren
|
|
PE20161475A1
(es)
|
2014-05-14 |
2017-01-08 |
Pfizer |
Pirazolopiridinas y pirazolopirimidinas
|
|
WO2015173684A1
(en)
|
2014-05-15 |
2015-11-19 |
Pfizer Inc. |
Crystalline form of 6-[(4r)-4-methyl-1,2-dioxido-1,2,6-thiadiazinan-2-yl]isoquinoline-1-carbonitrile
|
|
JP6572414B2
(ja)
|
2014-05-20 |
2019-09-11 |
ラクオリア創薬株式会社 |
ベンズイソオキサゾール誘導体塩
|
|
GB201409485D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
|
GB201409471D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
|
GB201409488D0
(en)
|
2014-05-28 |
2014-07-09 |
Euro Celtique Sa |
Pharmaceutical composition
|
|
EP3148992A1
(de)
|
2014-05-30 |
2017-04-05 |
Pfizer Inc. |
Benzolsulfonamide als kaliumkanalhemmer
|
|
ES2864079T3
(es)
|
2014-05-30 |
2021-10-13 |
Pfizer |
Derivados de carbonitrilo como moduladores selectivos del receptor de andrógenos
|
|
EP3154979B1
(de)
|
2014-06-12 |
2018-03-07 |
Pfizer Limited |
Imidazopyridazinderivate als modulatoren der gabaa-rezeptoraktivität
|
|
WO2015193768A1
(en)
|
2014-06-17 |
2015-12-23 |
Pfizer Inc. |
Aryl fused lactams as ezh2 modulators
|
|
AP2016009605A0
(en)
|
2014-06-17 |
2016-12-31 |
Pfizer |
Substituted dihydroisoquinolinone compounds
|
|
EP3166642B1
(de)
|
2014-06-18 |
2020-06-03 |
Audevard |
Transdermale formulierungen von pergolid und verwendungen davon
|
|
ES2843973T3
(es)
|
2014-06-27 |
2021-07-21 |
Celgene Corp |
Composiciones y métodos para inducir cambios conformacionales en cereblon y otras ubiquitina ligasas E3
|
|
WO2016009296A1
(en)
|
2014-07-16 |
2016-01-21 |
Pfizer Inc. |
N-acylpiperidine ether tropomyosin-related kinase inhibitors
|
|
WO2016009303A1
(en)
|
2014-07-17 |
2016-01-21 |
Pfizer Inc. |
Pharmaceutical combinations comprising gabapentin or pregabalin with nav1.7 inhibitors
|
|
WO2016009297A1
(en)
|
2014-07-18 |
2016-01-21 |
Pfizer Inc. |
Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators
|
|
TWI568365B
(zh)
*
|
2014-07-22 |
2017-02-01 |
蘇廷弘 |
抑菌複合物及其製造方法
|
|
WO2016020784A1
(en)
|
2014-08-05 |
2016-02-11 |
Pfizer Inc. |
N-acylpyrrolidine ether tropomyosin-related kinase inhibitors
|
|
AU2015305449B2
(en)
|
2014-08-22 |
2021-05-06 |
Celgene Corporation |
Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
|
|
HUE063851T2
(hu)
|
2014-08-22 |
2024-02-28 |
Cydex Pharmaceuticals Inc |
Frakcionált alkilezett ciklodextrin készítmények és eljárás ezek elõállítására és alkalmazására
|
|
WO2016034971A1
(en)
|
2014-09-04 |
2016-03-10 |
Pfizer Limited |
Sulfonamides derivatives as urat1 inhibitors
|
|
JOP20200195A1
(ar)
|
2014-09-08 |
2017-06-16 |
Sage Therapeutics Inc |
سترويدات وتركيبات نشطة عصبياً، واستخداماتها
|
|
WO2016044433A2
(en)
|
2014-09-16 |
2016-03-24 |
Biopharma Works |
Metformin derivatives
|
|
GB201417163D0
(en)
|
2014-09-29 |
2014-11-12 |
Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin |
Substituted pyrimidine derivatives useful in the treatment of autoimmune diseases
|
|
GB201417165D0
(en)
|
2014-09-29 |
2014-11-12 |
Provost Fellows & Scholars College Of The Holy Undivided Trinity Of Queen Elizabeth Near Dublin |
Treatments for Autoimmune Disease
|
|
WO2016067143A1
(en)
|
2014-10-28 |
2016-05-06 |
Pfizer Inc. |
N-(2-alkyleneimino-3-phenylpropyl)acetamide compounds and their use against pain and pruritus via inhibition of trpa1 channels
|
|
WO2016097918A1
(en)
|
2014-12-18 |
2016-06-23 |
Pfizer Inc. |
Pyrimidine and triazine derivatives and their use as axl inhibitors
|
|
TW201636342A
(zh)
|
2014-12-19 |
2016-10-16 |
武田藥品工業有限公司 |
煙黴醇衍生物
|
|
BR112017015536B1
(pt)
|
2015-01-22 |
2021-05-18 |
Phytoplant Research S.L |
métodos de purificação de canabinoides
|
|
DK3050574T3
(da)
|
2015-01-28 |
2020-01-20 |
Univ Bordeaux |
Anvendelse af plerixafor til behandling og/eller forebyggelse af akutte forværringer af kronisk obstruktiv lungesygdom
|
|
PT3253208T
(pt)
|
2015-02-02 |
2021-06-17 |
The Spanish National Cancer Res Centre |
Terapêuticas de combinação para utilização no tratamento do cancro da mama
|
|
JP2018504420A
(ja)
|
2015-02-06 |
2018-02-15 |
マリナス ファーマシューティカルズ インコーポレイテッド |
静注用ガナキソロン製剤ならびにてんかん重積状態および他の発作性障害の治療におけるその使用
|
|
EA031895B1
(ru)
|
2015-02-24 |
2019-03-29 |
Пфайзер Инк. |
Замещенные нуклеозидные производные, полезные в качестве агентов против рака
|
|
CN107847609A
(zh)
|
2015-03-13 |
2018-03-27 |
恩多塞特公司 |
用于治疗疾病的缀合物
|
|
US10702568B2
(en)
|
2015-03-19 |
2020-07-07 |
Cydex Pharmaceuticals, Inc. |
Compositions containing silymarin and sulfoalkyl ether cyclodextrin and methods of using the same
|
|
TW201642857A
(zh)
|
2015-04-06 |
2016-12-16 |
西建公司 |
以組合療法治療肝細胞癌
|
|
NL2014614B1
(en)
|
2015-04-10 |
2017-01-25 |
Pld Biochemistry B V |
Method and means for increasing antibodies against Borrelia burgdorferi and increasing antigen of Borrelia burgdorferi.
|
|
WO2016195476A1
(en)
|
2015-05-29 |
2016-12-08 |
Erasmus University Medical Center Rotterdam |
Treatment of cardiac arrhythmias
|
|
EP3310779B1
(de)
|
2015-06-19 |
2019-05-08 |
Novartis AG |
Verbindungen und zusammensetzungen zur hemmung der aktivität von shp2
|
|
WO2016203406A1
(en)
|
2015-06-19 |
2016-12-22 |
Novartis Ag |
Compounds and compositions for inhibiting the activity of shp2
|
|
ES2824576T3
(es)
|
2015-06-19 |
2021-05-12 |
Novartis Ag |
Compuestos y composiciones para inhibir la actividad de SHP2
|
|
SI3313818T1
(sl)
|
2015-06-26 |
2024-03-29 |
Celgene Corporation |
Postopki zdravljenja Kaposijevega sarkoma ali s KSHV povzročenega limfoma, z uporabo imunomodulatornih spojin in uporabe biomarkerjev
|
|
KR20180023968A
(ko)
|
2015-07-02 |
2018-03-07 |
셀진 코포레이션 |
혈액암 및 충실성 종양의 치료를 위한 병용 요법
|
|
WO2017007805A1
(en)
|
2015-07-09 |
2017-01-12 |
Gilead Sciences, Inc. |
Intravenous formulations of a late sodium current inhibitor
|
|
MX375424B
(es)
|
2015-07-31 |
2025-03-06 |
Pfizer |
Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-il carbamato y derivados de 1,1,1-trifluoro-4- hidroxibutan-2-il carbamato como inhibidores de magl
|
|
US20190054113A1
(en)
|
2015-09-30 |
2019-02-21 |
Sarepta Therapeutics, Inc. |
Methods for treating muscular dystrophy
|
|
CA3006865A1
(en)
|
2015-11-30 |
2017-06-08 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Formulations for intravenous injection of danirixin
|
|
WO2017098367A1
(en)
|
2015-12-10 |
2017-06-15 |
Pfizer Limited |
4-(biphen-3-yl)-1h-pyrazolo[3,4-c]pyridazine derivatives of formula (i) as gaba receptor modulators for use in the treatment of epilepsy and pain
|
|
WO2017111179A1
(en)
|
2015-12-24 |
2017-06-29 |
Takeda Pharmaceutical Company Limited |
Cocrystal, production method thereof, and medicament containing cocrystal
|
|
US10830762B2
(en)
|
2015-12-28 |
2020-11-10 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
|
|
WO2017120429A1
(en)
|
2016-01-07 |
2017-07-13 |
CS Pharmasciences, Inc. |
Selective inhibitors of clinically important mutants of the egfr tyrosine kinase
|
|
WO2017119732A1
(en)
|
2016-01-08 |
2017-07-13 |
Samsung Electronics Co., Ltd. |
Electronic device and operating method thereof
|
|
JP6929857B2
(ja)
|
2016-01-15 |
2021-09-01 |
ファイザー・インク |
6,7,8,9−テトラヒドロ−5H−ピリド[2,3−d]アゼピンドーパミンD3リガンド
|
|
CN115154619B
(zh)
|
2016-02-04 |
2025-11-28 |
西泽普研究与发展有限责任公司 |
受控释放和层状的环糊精包合物媒介物
|
|
PH12018501923B1
(en)
|
2016-03-08 |
2024-06-28 |
Sage Therapeutics Inc |
Neuroactive steroids, compositions, and uses thereof
|
|
US11753626B2
(en)
|
2016-03-09 |
2023-09-12 |
Beijing Percans Oncology Co., Ltd. |
Tumor cell suspension cultures and related methods
|
|
JP7305352B2
(ja)
*
|
2016-03-31 |
2023-07-10 |
武田薬品工業株式会社 |
イソキノリニルトリアゾロン錯体
|
|
JP7042255B2
(ja)
|
2016-04-29 |
2022-03-25 |
サレプタ セラピューティクス, インコーポレイテッド |
ヒトlmnaを標的にするオリゴヌクレオチド類縁体
|
|
CA2969295A1
(en)
|
2016-06-06 |
2017-12-06 |
Pfizer Inc. |
Substituted carbonucleoside derivatives, and use thereof as a prmt5 inhibitor
|
|
PT3468972T
(pt)
|
2016-06-14 |
2020-08-21 |
Novartis Ag |
Compostos e composições para inibir a atividade da shp2
|
|
KR20190024977A
(ko)
|
2016-06-30 |
2019-03-08 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
근육 이상증에 대한 엑손 스킵핑 올리고머
|
|
WO2018015465A1
(en)
*
|
2016-07-22 |
2018-01-25 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Virucidal compounds and uses thereof
|
|
MX2019001153A
(es)
|
2016-07-29 |
2019-06-10 |
Pfizer |
Peptidos ciclicos como antagonistas del receptor c5a.
|
|
SG10202100724UA
(en)
|
2016-07-29 |
2021-03-30 |
Sunovion Pharmaceuticals Inc |
Compounds and compositions and uses thereof
|
|
BR112019001407A2
(pt)
|
2016-07-29 |
2019-07-09 |
Sunovion Pharmaceuticals Inc. |
compostos e composições e usos dos mesmos
|
|
KR20230050474A
(ko)
|
2016-08-11 |
2023-04-14 |
오비드 테라퓨틱스 인크. |
간질 장애의 치료를 위한 방법 및 조성물
|
|
CN109803968A
(zh)
|
2016-08-15 |
2019-05-24 |
辉瑞公司 |
吡啶并嘧啶酮cdk2/4/6抑制剂
|
|
US10532102B2
(en)
|
2016-08-19 |
2020-01-14 |
Foresee Pharmaceuticals Co., Ltd. |
Pharmaceutical composition and methods of uses
|
|
ES2910833T3
(es)
*
|
2016-08-19 |
2022-05-13 |
Foresee Pharmaceuticals Co Ltd |
Composición farmacéutica y procedimientos de usos
|
|
US10391105B2
(en)
|
2016-09-09 |
2019-08-27 |
Marinus Pharmaceuticals Inc. |
Methods of treating certain depressive disorders and delirium tremens
|
|
WO2018068832A1
(en)
|
2016-10-11 |
2018-04-19 |
Euro-Celtique S.A. |
Hodgkin lymphoma therapy
|
|
CN110022857A
(zh)
|
2016-11-18 |
2019-07-16 |
艾库里斯抗感染治疗有限公司 |
基于改性环糊精和酸化剂的脒取代β-内酰胺化合物的新制剂、其制备及作为抗微生物药物组合物的用途
|
|
US10316021B2
(en)
|
2016-11-28 |
2019-06-11 |
Pfizer Inc. |
Heteroarylphenoxy benzamide kappa opioid ligands
|
|
ES3051834T3
(en)
|
2016-12-19 |
2025-12-30 |
Sarepta Therapeutics Inc |
Exon skipping oligomer conjugates for muscular dystrophy
|
|
NZ755416A
(en)
|
2016-12-19 |
2023-05-26 |
Sarepta Therapeutics Inc |
Exon skipping oligomer conjugates for muscular dystrophy
|
|
PT4122497T
(pt)
|
2016-12-19 |
2024-06-12 |
Sarepta Therapeutics Inc |
Conjugados oligoméricos de salto de exão para a distrofia muscular
|
|
JP7273723B2
(ja)
|
2016-12-20 |
2023-05-15 |
オリゴメリックス インコーポレイテッド |
タウオリゴマーの形成を阻害する新規キナゾリノン及びその使用方法
|
|
JP7273722B2
(ja)
|
2016-12-20 |
2023-05-15 |
オリゴメリックス インコーポレイテッド |
タウオリゴマーの形成を阻害する新規ベンゾフラン、ベンゾチオフェン及びインドール類似体並びにそれらの使用方法
|
|
MX2019008626A
(es)
|
2017-01-20 |
2019-09-19 |
Pfizer |
Derivados de 1,1,1-trifluoro-3-hidroxipropan-2-ilcarbamato como inhibidores de monoacilglicerol lipasa (magl).
|
|
JP2020506903A
(ja)
|
2017-01-23 |
2020-03-05 |
ファイザー・インク |
Magl阻害薬としての複素環式スピロ化合物
|
|
JP7062010B2
(ja)
|
2017-01-27 |
2022-05-02 |
セルジーン コーポレイション |
3-(1-オキソ-4-((4-((3-オキソモルホリノ)メチル)ベンジル)オキシ)イソインドリン-2-イル)ピペリジン-2,6-ジオン及びそのアイソトポログ
|
|
EP3582815A1
(de)
|
2017-02-16 |
2019-12-25 |
Sunovion Pharmaceuticals Inc. |
Verfahren zur behandlung von schizophrenie
|
|
CN110520127B
(zh)
|
2017-03-26 |
2023-05-16 |
武田药品工业株式会社 |
作为gpr6的调节剂的经哌啶基取代的杂芳族羧酰胺和经哌嗪基取代的杂芳族羧酰胺
|
|
ES2994451T3
(en)
|
2017-04-20 |
2025-01-24 |
Atyr Pharma Inc |
Compositions for treating lung inflammation
|
|
MX2019013053A
(es)
*
|
2017-05-03 |
2020-02-07 |
Cydex Pharmaceuticals Inc |
Composicion que contiene ciclodextrina y busulfan.
|
|
GB201709402D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro Celtique Sa |
Compounds for treating t-pll
|
|
GB201709405D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro Celtique Sa |
Compounds for treating ovarian cancer
|
|
GB201709403D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro Celtique Sa |
Compounds for treating sarcoma
|
|
GB201709406D0
(en)
|
2017-06-13 |
2017-07-26 |
Euro-Cletique S A |
Compounds for treating TNBC
|
|
JOP20180057A1
(ar)
|
2017-06-15 |
2019-01-30 |
Takeda Pharmaceuticals Co |
مركبات رابع هيدروبيريدو بيرازين والتي تعمل كمعدلات gpr6
|
|
CN111132972B
(zh)
|
2017-06-22 |
2024-07-12 |
克拉德夫制药有限公司 |
人sting的小分子调节剂
|
|
EP4201399A3
(de)
*
|
2017-06-30 |
2023-08-09 |
Celgene Corporation |
Zusammensetzungen und verfahren zur verwendung von 2-(4-chlorphenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoracetamid
|
|
CN111093627B
(zh)
|
2017-07-11 |
2024-03-08 |
吉利德科学公司 |
用于治疗病毒感染的包含rna聚合酶抑制剂和环糊精的组合物
|
|
MX2020000523A
(es)
|
2017-08-02 |
2020-08-20 |
Sunovion Pharmaceuticals Inc |
Compuestos de isocromano y usos de los mismos.
|
|
TWI808092B
(zh)
|
2017-08-30 |
2023-07-11 |
中國大陸商北京軒義醫藥科技有限公司 |
作為干擾素基因調節劑之刺激劑的環狀二核苷酸
|
|
JP7447002B2
(ja)
|
2017-09-11 |
2024-03-11 |
クルーゾン・ファーマシューティカルズ・インコーポレイテッド |
SHP2のオクタヒドロシクロペンタ[c]ピロールのアロステリック阻害剤
|
|
EA201991450A1
(ru)
|
2017-09-22 |
2019-12-30 |
Сарепта Терапьютикс, Инк. |
Конъюгаты олигомеров для пропуска экзона при мышечной дистрофии
|
|
TW201920108A
(zh)
|
2017-09-25 |
2019-06-01 |
日商武田藥品工業有限公司 |
N-(氰基取代之苄基或吡啶基甲基)-3-羥基吡啶醯胺衍生物
|
|
JP2020536060A
(ja)
|
2017-09-28 |
2020-12-10 |
サレプタ セラピューティクス, インコーポレイテッド |
筋ジストロフィーを処置するための併用療法
|
|
JP2020536058A
(ja)
|
2017-09-28 |
2020-12-10 |
サレプタ セラピューティクス, インコーポレイテッド |
筋ジストロフィーを処置するための併用療法
|
|
EP3687519A1
(de)
|
2017-09-28 |
2020-08-05 |
Sarepta Therapeutics, Inc. |
Kombinationstherapien zur behandlung von muskeldystrophie
|
|
CA3089490A1
(en)
|
2018-01-29 |
2019-08-01 |
Phytoplant Research S.L |
Methods of purifying cannabinoids using liquid:liquid chromatography
|
|
TW201942115A
(zh)
|
2018-02-01 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌藥之經取代的喹唑啉和吡啶並嘧啶衍生物
|
|
TW201942116A
(zh)
|
2018-02-09 |
2019-11-01 |
美商輝瑞股份有限公司 |
作為抗癌劑之四氫喹唑啉衍生物
|
|
TWI834637B
(zh)
|
2018-03-01 |
2024-03-11 |
日商武田藥品工業有限公司 |
六氫吡啶基-3-(芳氧基)丙醯胺及丙酸酯
|
|
US10538542B2
(en)
|
2018-03-15 |
2020-01-21 |
Pfizer Inc. |
Cyclopentane-based modulators of STING (stimulator of interferon genes)
|
|
CN118286225A
(zh)
|
2018-04-26 |
2024-07-05 |
辉瑞公司 |
作为细胞周期蛋白依赖性激酶抑制剂的2-氨基-吡啶或2-氨基-嘧啶衍生物
|
|
US10765760B2
(en)
|
2018-05-29 |
2020-09-08 |
Sarepta Therapeutics, Inc. |
Exon skipping oligomer conjugates for muscular dystrophy
|
|
EP3801481A1
(de)
|
2018-05-30 |
2021-04-14 |
Convert Pharmaceuticals SA |
Prodrugs und medizinische verwendungen davon
|
|
CA3101975A1
(en)
|
2018-06-01 |
2019-12-05 |
Bayer Cropscience Lp |
Stabilized fungicidal composition comprising cyclodextrin
|
|
EP4219717A3
(de)
|
2018-06-13 |
2023-12-20 |
Sarepta Therapeutics, Inc. |
Exon-skipping-oligomere für muskeldystrophie
|
|
WO2019243823A1
(en)
|
2018-06-21 |
2019-12-26 |
Curadev Pharma Limited |
Azaheterocyclic small molecule modulators of human sting
|
|
CA3106510A1
(en)
|
2018-07-19 |
2020-01-23 |
Pfizer Inc. |
Heterocyclic spiro compounds as magl inhibitors
|
|
AU2019312366B2
(en)
|
2018-07-26 |
2025-08-14 |
Atyr Pharma, Inc. |
Compositions and methods for treating NRP2-associated diseases
|
|
TW202449155A
(zh)
|
2018-07-27 |
2024-12-16 |
美商薩羅塔治療公司 |
用於肌肉萎縮症之外顯子跳躍寡聚物
|
|
EP3846853A1
(de)
|
2018-09-04 |
2021-07-14 |
Ecole Polytechnique Federale De Lausanne (Epfl) |
Viruzide nanopartikel und verwendung davon gegen influenzavirus
|
|
WO2020076728A1
(en)
|
2018-10-08 |
2020-04-16 |
Takeda Pharmaceutical Company Limited |
SUBSTITUTED OXAZINOPTERIDINONES AS INHIBITORS OF mTOR
|
|
US11142525B2
(en)
|
2018-11-15 |
2021-10-12 |
Pfizer Inc. |
Azalactam compounds as HPK1 inhibitors
|
|
SG11202104585YA
(en)
|
2018-11-29 |
2021-06-29 |
Pfizer |
Pyrazoles as modulators of hemoglobin
|
|
US11266662B2
(en)
|
2018-12-07 |
2022-03-08 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in prophylaxis and treatment of postpartum depression
|
|
ES3041602T3
(en)
|
2018-12-10 |
2025-11-13 |
Sq Innovation Ag |
Pharmaceutical compositions of furosemide and uses thereof
|
|
BR112021011018A2
(pt)
|
2018-12-13 |
2021-08-31 |
Sarepta Therapeutics, Inc. |
Conjugados de oligômero para exon skipping para distrofia muscular
|
|
EP3897626B1
(de)
|
2018-12-18 |
2025-09-10 |
Mundipharma International Corporation Limited |
Tinostamustin zur behandlung von multiplem myelom
|
|
AU2020204925B2
(en)
|
2019-01-03 |
2025-11-20 |
Cyclarity Therapeutics, Inc. |
Cyclodextrin dimers, compositions thereof, and uses thereof
|
|
ES3058386T3
(es)
|
2019-01-04 |
2026-03-10 |
Sq Innovation Ag |
Composiciones farmacéuticas de furosemida
|
|
EP3906020B1
(de)
|
2019-01-04 |
2025-12-31 |
SQ Innovation AG |
Pharmazeutische zusammensetzungen von torsemid und verwendungen davon
|
|
SG11202107226VA
(en)
|
2019-01-23 |
2021-08-30 |
Pfizer |
Polymorph form of a monophosphate hydrate salt of a known tetrahydroisoquinoline derivative
|
|
CA3128155C
(en)
|
2019-01-31 |
2023-09-19 |
Pfizer Inc. |
3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2
|
|
WO2020157257A1
(en)
|
2019-02-01 |
2020-08-06 |
H. Lundbeck A/S |
Injectable carbamazepine composition essentially free of 10-br-carbamazepine
|
|
JP7703449B2
(ja)
|
2019-03-14 |
2025-07-07 |
スミトモ・ファーマ・アメリカ・インコーポレイテッド |
イソクロマニル化合物の塩およびその結晶体、ならびにそれらの製造方法、治療用途および医薬組成物
|
|
WO2020198053A1
(en)
|
2019-03-22 |
2020-10-01 |
Takeda Pharmaceutical Company Limited |
2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-6-yl)-4-methylbenzamide derivatives and similar compounds as ripk2 inhibitors for treating e.g. autoimmune diseases
|
|
EP3946376A1
(de)
|
2019-03-28 |
2022-02-09 |
Sarepta Therapeutics, Inc. |
Verfahren zur behandlung von muskeldystrophie mit casimersen
|
|
WO2020214763A1
(en)
|
2019-04-18 |
2020-10-22 |
Sarepta Therapeutics, Inc. |
Compositions for treating muscular dystrophy
|
|
JP7574215B2
(ja)
|
2019-04-29 |
2024-10-28 |
ソレント セラピューティクス,エルエルシー |
MRGX2の阻害薬である3-アミノ-4H-ベンゾ[e][1,2,4]チアジアジン1,1-ジオキシド誘導体
|
|
EP3987029A1
(de)
|
2019-06-19 |
2022-04-27 |
Sarepta Therapeutics, Inc. |
Verfahren zur behandlung von muskeldystrophie
|
|
US11339159B2
(en)
|
2019-07-17 |
2022-05-24 |
Pfizer Inc. |
Toll-like receptor agonists
|
|
KR20220044753A
(ko)
|
2019-07-25 |
2022-04-11 |
큐라데브 파마 프라이버트 리미티드 |
아세틸 조효소 a 신테타제 단쇄 2(acss2)의 소분자 억제제
|
|
EP4009982A4
(de)
|
2019-08-05 |
2023-08-09 |
Marinus Pharmaceuticals, Inc. |
Ganaxolon zur verwendung bei der behandlung von status epilepticus
|
|
CA3149914A1
(en)
|
2019-08-06 |
2021-02-11 |
L.E.A.F. Holdings Group Llc |
Processes of preparing polyglutamated antifolates and uses of their compositions
|
|
TWI873185B
(zh)
|
2019-09-16 |
2025-02-21 |
日商武田藥品工業股份有限公司 |
唑稠合之嗒-3(2h)-酮衍生物
|
|
PH12022550709A1
(en)
|
2019-09-25 |
2023-03-27 |
Pfizer |
Polyheterocyclic modulators of sting (stimulator of interferon genes)
|
|
US20210145816A1
(en)
|
2019-11-15 |
2021-05-20 |
Cyclolab Cyclodextrin Research And Development Laboratory Ltd. |
Pharmaceutical formulation of lonafarnib with a sulfobutylether beta-cyclodextrin
|
|
CN115038723A
(zh)
|
2019-11-18 |
2022-09-09 |
锡德克斯药物公司 |
烷基化环糊精组合物及其制备和使用方法
|
|
KR20220110243A
(ko)
|
2019-12-02 |
2022-08-05 |
셀진 코포레이션 |
암의 치료를 위한 요법
|
|
AU2020395254B2
(en)
|
2019-12-06 |
2026-04-02 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in treating tuberous sclerosis complex
|
|
EP4103278A1
(de)
|
2020-02-12 |
2022-12-21 |
Curadev Pharma Pvt. Ltd. |
Niedermolekulare stachelantagonisten
|
|
AR121683A1
(es)
|
2020-03-31 |
2022-06-29 |
Takeda Pharmaceuticals Co |
Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4
|
|
AR121682A1
(es)
|
2020-03-31 |
2022-06-29 |
Takeda Pharmaceuticals Co |
Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4
|
|
JP2021167301A
(ja)
|
2020-04-08 |
2021-10-21 |
ファイザー・インク |
Cdk2阻害剤に対する腫瘍適応を抑制するためのcdk4/6およびcdk2阻害剤による同時処置
|
|
EP4143186A1
(de)
|
2020-05-01 |
2023-03-08 |
Pfizer Inc. |
Azalactamverbindungen als hpk1-inhibitoren
|
|
KR20230005893A
(ko)
|
2020-05-04 |
2023-01-10 |
다케다 야쿠힌 고교 가부시키가이샤 |
내강 작용 n-(피페리딘-4-일)벤즈아미드 유도체
|
|
WO2021224818A1
(en)
|
2020-05-08 |
2021-11-11 |
Pfizer Inc. |
Isoindolone compounds as hpk1 inhibitors
|
|
DK4172145T3
(da)
|
2020-06-30 |
2026-07-20 |
Reunion Neuroscience Inc |
Tryptamin-prodrugs som serotonin-receptor-aktivatorer til behandling af f.eks. depression
|
|
US11767317B1
(en)
|
2020-06-30 |
2023-09-26 |
Poxel Sa |
Methods of synthesizing enantiopure deuterium-enriched pioglitazone
|
|
US11319313B2
(en)
|
2020-06-30 |
2022-05-03 |
Poxel Sa |
Crystalline forms of deuterium-enriched pioglitazone
|
|
TW202214641A
(zh)
|
2020-06-30 |
2022-04-16 |
美商艾瑞生藥股份有限公司 |
Her2突變抑制劑
|
|
US20230242539A1
(en)
|
2020-07-15 |
2023-08-03 |
Pfizer Inc. |
Polymorphs of (1S,2S,3S,5R)-3-((6-(Difluoromethyl)-5-Fluoro-1,2,3,4-Tetrahydroisoquinolin-8-YL)OXY)-5-(4-Methyl-7H-Pyrrolo[2,3-D]Pyrimidin-7-YL)Cyclopentane-1,2-DIOL Mono-Hydrochloride
|
|
US20240116937A1
(en)
|
2020-07-15 |
2024-04-11 |
Pfizer Inc. |
Polymorph of (1S,2S,3S,5R)-3-((6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydroisoquinolin-8-yl)oxy)-5-(4-methyl-7H-pyrrolo[2,3-D]pyrimidin-7-yl)cyclopentane-1,2-diol
|
|
WO2022018667A1
(en)
|
2020-07-24 |
2022-01-27 |
Pfizer Inc. |
Combination therapies using cdk2 and cdc25a inhibitors
|
|
GB202011812D0
(en)
|
2020-07-29 |
2020-09-09 |
Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid |
Compounds
|
|
GB202011811D0
(en)
|
2020-07-29 |
2020-09-09 |
Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid |
Compounds
|
|
TW202229239A
(zh)
|
2020-09-23 |
2022-08-01 |
日商武田藥品工業股份有限公司 |
作為ripk2抑制劑之3-(6-胺基吡啶-3-基)苯甲醯胺衍生物
|
|
US12698348B2
(en)
|
2020-09-24 |
2026-08-04 |
Cydex Pharmaceuticals, Inc. |
Alkylated cyclodextrin compositions and processes for preparing and using the same
|
|
IL301991A
(en)
|
2020-10-09 |
2023-06-01 |
Napa Therapeutics Ltd |
Heteroaryl amide inhibitors for CD38
|
|
US11964978B2
(en)
|
2021-03-18 |
2024-04-23 |
Pfizer Inc. |
Modulators of STING (stimulator of interferon genes)
|
|
EP4313151A1
(de)
|
2021-03-31 |
2024-02-07 |
Sevenless Therapeutics Limited |
Sos1-inhibitoren und ras-inhibitoren zur verwendung bei der behandlung von schmerzen
|
|
GB202104609D0
(en)
|
2021-03-31 |
2021-05-12 |
Sevenless Therapeutics Ltd |
New Treatments for Pain
|
|
EP4320121A2
(de)
|
2021-04-07 |
2024-02-14 |
LifeArc |
2,4-diaminopyrimidinderivate als ulk1/2-inhibitoren und deren verwendung
|
|
EP4359082A1
(de)
|
2021-06-26 |
2024-05-01 |
Array BioPharma Inc. |
Her2-mutationsinhibitoren
|
|
KR20240044458A
(ko)
|
2021-08-05 |
2024-04-04 |
브리스톨-마이어스 스큅 컴퍼니 |
Her2 억제제로서 사용하기 위한 트리시클릭 융합된 피리미딘 화합물
|
|
ES3066682T3
(en)
|
2021-08-11 |
2026-05-14 |
Curadev Pharma Pvt Ltd |
Small molecule urea derivatives as sting antagonists
|
|
CA3228528A1
(en)
|
2021-08-11 |
2023-02-16 |
Monali BANERJEE |
Small molecule sting antagonists
|
|
EP4162933A1
(de)
|
2021-10-08 |
2023-04-12 |
Algiax Pharmaceuticals GmbH |
Verbindung zur behandlung von nicht-alkoholischer fettlebererkrankung und verwandten erkrankungen
|
|
US20250042918A1
(en)
|
2021-12-01 |
2025-02-06 |
Fundación Del Sector Públlco Estatal Centro Nacional De Investigaciones Oncológicas Carlos III |
Compounds
|
|
EP4493693A1
(de)
|
2022-03-17 |
2025-01-22 |
Sarepta Therapeutics, Inc. |
Phosphorodiamidat-morpholino-oligomerkonjugate
|
|
CA3255222A1
(en)
|
2022-03-30 |
2023-10-05 |
Takeda Pharmaceutical Company Limited |
N-(pyrrolidin-3-yl or piperidin-4-yl)acetamide derivatives
|
|
AR129012A1
(es)
|
2022-04-07 |
2024-07-03 |
Takeda Pharmaceuticals Co |
Derivados de piridazina fusionados
|
|
US12655157B2
(en)
|
2022-07-29 |
2026-06-16 |
Pfizer Inc. |
Spiro[benzo[d]thiazole-6 ,4′-piperidine as ACC inhibitors
|
|
WO2024033845A1
(en)
|
2022-08-10 |
2024-02-15 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound
|
|
EP4593855A1
(de)
|
2022-09-28 |
2025-08-06 |
Altos Labs, Inc. |
Expression von regenerationsfaktoren in alternden/alternierenden zellen
|
|
EP4598538A1
(de)
|
2022-10-05 |
2025-08-13 |
Sevenless Therapeutics Limited |
Neue schmerzbehandlungen
|
|
WO2024105364A1
(en)
|
2022-11-15 |
2024-05-23 |
Curadev Pharma Ltd |
Heterocyclic inhibitors of cdc-like kinases
|
|
AU2023420130A1
(en)
|
2022-12-30 |
2025-08-14 |
Cornell University |
Acid cyclodextrins for the treatment of lipofuscin buildups and ocular diseases
|
|
KR20250135317A
(ko)
|
2023-01-26 |
2025-09-12 |
다케다 야쿠힌 고교 가부시키가이샤 |
신경퇴행성 질환의 치료에 유용한 1-아미노-4-페닐프탈라진 유도체
|
|
KR20250170647A
(ko)
|
2023-04-14 |
2025-12-05 |
다케다 야쿠힌 고교 가부시키가이샤 |
Nlrp3 억제제로서의 피라졸로피리미딘 유도체
|
|
JP2026517851A
(ja)
|
2023-05-05 |
2026-06-02 |
ユーロ-セルティーク エス.エイ. |
がんを処置するための組合せ
|
|
GB2631397A
(en)
|
2023-06-28 |
2025-01-08 |
Sevenless Therapeutics Ltd |
New treatments for pain
|
|
GB2633813A
(en)
|
2023-09-21 |
2025-03-26 |
Sevenless Therapeutics Ltd |
New treatments for pain
|
|
WO2025074305A1
(en)
|
2023-10-04 |
2025-04-10 |
Takeda Pharmaceutical Company Limited |
N-(1-(aminomethyl)cyclopropyl)(aryl or heteroaryl) carboxamide derivatives
|
|
WO2025083426A1
(en)
|
2023-10-20 |
2025-04-24 |
Sevenless Therapeutics Limited |
New treatments for pain
|
|
GB202319181D0
(en)
|
2023-12-14 |
2024-01-31 |
Imperial College Innovations Ltd |
Nora Inhibitors
|
|
WO2025137437A1
(en)
|
2023-12-21 |
2025-06-26 |
Pfizer Inc. |
Solid forms of a gabaa receptor modulator and methods of its use
|
|
WO2025146548A1
(en)
|
2024-01-04 |
2025-07-10 |
Sevenless Therapeutics Limited |
Sos1 inhibitors useful to treat pain and cancer
|
|
WO2025229624A2
(en)
|
2024-05-02 |
2025-11-06 |
Napa Therapeutics Limited |
New cd38 inhibitors
|
|
WO2025231370A1
(en)
|
2024-05-02 |
2025-11-06 |
Napa Therapeutics Limited |
Inhibitors of cd38
|
|
TW202608877A
(zh)
|
2024-05-07 |
2026-03-01 |
日商武田藥品工業股份有限公司 |
雜環化合物
|
|
US12383633B1
(en)
|
2024-10-01 |
2025-08-12 |
Zymeron Corporation |
Injectable formulations of PARP inhibitors and uses thereof
|
|
WO2026073303A1
(en)
*
|
2024-10-04 |
2026-04-09 |
Race Oncology Ltd |
Pharmaceutical compositions suitable for intravenous administration
|
|
WO2026085322A1
(en)
|
2024-10-18 |
2026-04-23 |
Aardvark Therapeutics Inc. |
Isoflavonoid formulations and methods of use
|
|
WO2026088070A1
(en)
|
2024-10-24 |
2026-04-30 |
Pfizer Inc. |
Compounds
|
|
GB202416727D0
(en)
|
2024-11-13 |
2024-12-25 |
Imperial College Innovations Ltd |
RAB27 inhibitors
|
|
WO2026126059A1
(en)
|
2024-12-09 |
2026-06-18 |
Takeda Pharmaceutical Company Limited |
Heterocyclic compound
|